3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS. THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES FIELD OF THE INVENTION The invention relates to 3H-[l,2,3]triazolo[4,5-d]pyrimidine compounds, compositions comprising a 3H-[l,2,3]triazolo[4,5-d]pyrimidine compound, methods of synthesizing these compounds, and methods for treating PI3K-related diseases. The invention also relates to methods for treating mTOR-related diseases. BACKGROUND OF THE INVENTION Phosphatidylinositol (hereinafter abbreviated as "PI") is one of the phospholipids in cell membranes. In recent years it has become clear that PI plays an important role also in intracellular signal transduction. It is well recognized in the art that PI (4,5) bisphosphate (PI(4,5)P2 or PIP2) is degraded into diacylglycerol and inositol (1,4,5) triphosphate by phospholipase C to induce activation of protein kinase C and intracellular calcium mobilization, respectively [M. J. Berridge et al, Nature, 312, 315 (1984); Y. Nishizuka, Science, 225, 1365 (1984)]. In the late 1980s, phosphatidylinositol-3 kinase ("PI3K") was found to be an enzyme that phosphorylates the 3-position of the inositol ring of phosphatidylinositol [D. Whitman et al, Nature, 332, 664 (1988)]. When PI3K was discovered, it was originally considered to be a single enzyme. Recently however, it was clarified that a plurality of PI3K subtypes exists. Three major subtypes of PI3Ks have now been identified on the basis of their in vitro substrate specificity, and these three are designated class I (a&b), class II, and class III [B. Vanhaesebroeck, Trend in Biol Sci., 22, 267(1997)]. The class la PI3K subtype has been most extensively investigated to date. Within the class la subtype there are three isoforms (α, ß, & δ) that exist as hetero dimers of a catalytic 110-kDa subunit and regulatory subunits of 50-85kDa. The regulatory subunits contain SH2 domains that bind to phosphorylated tyrosine residues within growth factor receptors or adaptor molecules and thereby localize PI3K to the inner cell membrane. At the inner cell membrane PI3K converts PIP2 to PIP3 (phosphatidylinositol-3,4,5-trisphosphate) that serves to localize the downstream effectors PDK1 and Akt to the inner cell membrane where Akt activation occurs. Activated Akt mediates a diverse array of effects including inhibition of apoptosis, cell cycle progression, response to insulin signaling, and cell proliferation. Class la PI3K subtypes also contain Ras binding domains (RBD) that allow association with activated Ras providing mother mechanism for PI3K membrane localization. Activated, oncogenic forms of growth factor receptors, Ras, and even PI3K kinase have been shown to aberrantly elevate signaling in the PI3K/Akt/mTOR pathway resulting in cell transformation. As a central component of the PI3K/Akt/mTOR signaling pathway PI3K (particularly the class la a isoform) has become a major therapeutic target in cancer drug discovery. Substrates for class I PI3Ks are PI, PI(4)P and PI(4,5)P2, with PI(4,5)P2 being the most favored. Class I PDKs are further divided into two groups, class la and class lb, because of their activation mechanism and associated regulatory subunits. The class lb PI3K is pllOy that is activated by interaction with G protein-coupled receptors. Interaction between pllOy and G protein-coupled receptors is mediated by regulatory subunits of 110, 87, and 84 kDa. PI and PI(4)P are the known substrates for class II PDKs; PI(4,5)P2 is not a substrate for the enzymes of this class. Class II PDKs include PDK C2α, C2ß and C2 isoforms, which contain C2 domains at the C terminus, implying that their activity is regulated by calcium ions. The substrate for class III PDKs is PI only. A mechanism for activation of the class III PDKs has not been clarified. Because each subtype has its own mechanism for regulating activity, it is likely that activation mechanism(s) depend on stimuli specific to each respective class of PDK. The compound PI103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol) has been reported to inhibit both PDKa and PDK as well as the mTOR enzymes with IC50 values of 2, 3, and 50-80 nM respectively. I.P. dosing in mice of this compound in human tumor xenograft models of cancer demonstrated activity against a number of human tumor models, including the glioblastoma (PTEN null U87MG), prostate (PC3), breast (MDA-MB-468 and MDA-MB-435) colon carcinoma (HCT 116); and ovarian carcinoma (SKOV3 and IGROV-1); (Raynaud et al, Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases, Cancer Res. 2007 67: 5840-5850). The compound ZSTK474 (2-(2-difluoromethylbenzoimidazol-l-yl)-4, 6-dimorpholino-l, 3,5-triazine) has been reported to inhibit PDKa and PI3K but not the mTOR enzymes with an IC50 values of 16, 4.6 and > 10,000 nM respectively (Dexin Kong and Takao Yamori, ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms, Cancer Science, 2007, 98:10 1638-1642). Chronic oral administration of ZSTK474 in mouse human xenograft cancer models, completely inhibited growth which originated from a non-small-cell lung cancer (A549), a prostate cancer (PC-3), and a colon cancer (WiDr) at a dose of 400 mg/kg. (Yaguchi et al, Antitumor Activity of ZSTK474, a New Phosphatidylinositol 3-Kinase Inhibitor, J. Natl. Cancer Inst. 98: 545-556). The compound NVP-BEZ-235 (2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-lH-imidazo[4,5-c]quinolin-l-yl)phenyl)propanenitrile) has been reported to inhibit both PDKα and PI3K as well as the mTOR enzymes with IC50 values 4, 5, and "nanomolar". Testing in human tumor xenograft models of cancer demonstrated activity against human tumor models of prostrate (PC-3) and glioblastoma (U-87) cancer (Verheijen, J.C. and Zask, A., Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs, Drugs Fut. 2007, 32 (6): 537-547). The compound SF-1126 (a prodrug form of LY-294002, which is 2-(4-morpholinyl)-8-phenyl-4H-l-benzopyran-4-one) has been reported to be "a pan-PI3K inhibitor". It is active in preclinical mouse cancer models of prostate, breast, ovarian, lung, multiple myeloma, and brain cancers. It began clinical trials in April, 2007 for the solid tumors endometrial, renal cell, breast, hormone refractory prostate and ovarian cancers. (Verheijen, J.C. and Zask, A., Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs, Drugs Fut. 2007, 32 (6): 537-547). Exelixis Inc. (So. San Francisco, CA) recently filed INDs for XL-147 (a selective pan-PI3K inhibitor of unknown structure) and XL-765 (a mixed inhibitor of mTOR and POKof unknown structure), which were reported to be potentially useful as anticancer agents. TargeGen's short-acting mixed inhibitor of PI3Ky and 5, TG-100115, is in phase I/II trials for treatment of infarct following myocardial ischemia-reperfusion injury. Cerylid's antithrombotic PI3KJ3 inhibitor CBL-1309 (structure unknown) has completed preclinical toxicology studies. According to (Verheijen, J.C. and Zask, A., Phosphatidylinositol 3-kinase (PI3K) inhibitors as anticancer drugs, Drugs Fut. 2007, 32 (6): 537-547), Although it seems clear that inhibition of the a isoform is essential for the antitumor activity of PI3K inhibitors, it is not clear whether a more selective inhibitor of a particular PI3K isoform may lead to fewer unwanted biological effects. It has recently been reported that non-PI3Ka class I isoforms (PI3Kp, 8 and ) have the ability to induce oncogenic transformation of cells, suggesting that nonisoform- specific inhibitors may offer enhanced therapeutic potential over specific inhibitors. Selectivity versus other related kinases is also an important consideration for the development of PI3K inhibitors. While selective inhibitors may be preferred in order to avoid unwanted side effects, there have been reports that inhibition of multiple targets in the PI3K/Akt pathway (e.g., PI3Ka and mTOR [mammalian target of rapamycin]) may lead to greater efficacy. It is possible that lipid kinase inhibitors may parallel protein kinase inhibitors in that nonselective inhibitors may also be brought forward to the clinic. Mammalian Target of Rapamycin, mTOR, is a cell-signaling protein that regulates the response of tumor cells to nutrients and growth factors, as well as controlling tumor blood supply through effects on Vascular Endothelial Growth Factor, VEGF. Inhibitors of mTOR starve cancer cells and shrink tumors by inhibiting the effect of mTOR. All mTOR inhibitors bind to the mTOR kinase. This has at least two important effects. First, mTOR is a downstream mediator of the PDK/Akt pathway. The PI3K/Akt pathway is thought to be over activated in numerous cancers and may account for the widespread response from various cancers to mTOR inhibitors. The over-activation of the upstream pathway would normally cause mTOR kinase to be over activated as well. However, in the presence of mTOR inhibitors, this process is blocked. The blocking effect prevents mTOR from signaling to downstream pathways that control cell growth. Over-activation of the PDK/Akt kinase pathway is frequently associated with mutations in the PTEN gene, which is common in many cancers and may help predict what tumors will respond to mTOR inhibitors. The second major effect of mTOR inhibition is anti-angiogenesis, via the lowering of VEGF levels. In lab tests, certain chemotherapy agents were found to be more effective in the presence of mTOR inhibitors. George, J.N., et al, Cancer Research, 61, 1527-1532, 2001. Additional lab results have shown that some rhabdomyosarcoma cells die in the presence of mTOR inhibitors. The complete functions of the mTOR kinase and the effects of mTOR inhibition are not completely understood. There are three mTOR inhibitors, which have progressed into clinical trials. These compounds are Wyeth's Torisel, also known as 42-(3-hydroxy-2-(hydroxymethyl)-rapamycin 2-methylpropanoate, CCI-779 or Temsirolimus; Novartis' Everolimus, also known as 42-O-(2-hydroxyethyl)-rapamycin, or RAD 001; and Ariad's AP23573 also known as 42-(dimethylphopsinoyl)-rapamycin. The FDA has approved Torisel for the treatment of advanced renal cell carcinoma. In addition, Torisel is active in a NOS/SCID xenograft mouse model of acute lymphoblastic leukemia [Teachey et al, Blood, 107(3), 1149-1155, 2006]. Everolimus is in a phase II clinical study for patients with Stage IV Malignant Melanoma. AP23573 has been given orphan drug and fast-track status by the FDA for treatment of soft-tissue and bone sarcomas. The three mTOR inhibitors have non-linear, although reproducible pharmacokinetic profiles. Mean area under the curve (AUC) values for these drugs increase at a less than dose related way. The three compounds are all semi-synthetic derivatives of the natural macrolide antibiotic rapamycin. It would be desirable to find fully synthetic compounds, which inhibit mTOR that are more potent and exhibit improved pharmacokinetic behaviors. In view of the foregoing information, PI3K inhibitors and mTOR inhibitors are expected to be novel types of medicaments useful against cell proliferation disorders, especially as carcinostatic agents. Thus, it would be advantageous to have new PI3K inhibitors and mTOR inhibitors as potential treatment regimens for mTOR- and PI3K-related diseases. The instant invention is directed to these and other important ends. SUMMARY OF THE INVENTION In one aspect, the invention provides a compound of the Formula 1: (Formula Removed) or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined below. In other aspects, the invention provides pharmaceutical compositions comprising compounds or pharmaceutically acceptable salts of compounds of the present formula 1. In one aspect, the compounds or pharmaceutically acceptable salts thereof of the present formula 1 are useful as mTOR inhibitors. In one aspect, the compounds or pharmaceutically acceptable salts thereof of the present formula 1 are useful as PI3K inhibitors. In one aspect, the invention provides methods for treating an mTOR-related disorder, comprising administering to a mammal in need thereof, the compounds or pharmaceutically acceptable salts of compounds of the present formula 1 in an amount effective to treat an mTOR-related disorder. In one aspect, the invention provides methods for treating a PI3K-related disorder, comprising administering to a mammal in need thereof the compounds or pharmaceutically acceptable salts of compounds of the present formula 1 in an amount effective to treat a PI3K-related disorder. In other aspects, the invention provides further methods of synthesizing the compounds or pharmaceutically acceptable salts of compounds of the present formula 1. DETAILED DESCRIPTION OF THE INVENTION In one aspect, the invention provides a compound of the Formula 1: (Formula Removed) or a pharmaceutically acceptable salt thereof, wherein A is -O-, -CH2O-, or-S(O)m-; m is 0, 1, or 2; Ar is phenyl, naphthyl, or a nitrogen-containing mono- or bicyclic heteroaryl; R1 is independently C1-C6alkyl, C6-C14aryl, C1-C9heteroaryl, C2-C6alkenyl, C2-C6alkynyl, or C3- C8cycloalkyl; or two R1 groups on the same carbon atom, when taken together with the carbon to which they are attached, optionally form a carbonyl (C=0) group; n is 0, 1, 2, or 3; R2 is independently halogen; C1-C6alkyl; C2-C6alkenyl; C1-C6alkoxy; C2-C6alkynyl; C3- C8cycloalkyl; C6-C14aryl; C1-C9heteroaryl; hydroxyl; C1-C6hydroxylalkyl-; -NR4R5; -NO2; - CHO; -CN; -C(O)NR4R5; R6C(O)NH-; -CO2H; -CF3; -OCF3; R4R5NC(O)NH-; or R6OC(O)NH-; r is O, 1,2, 3,4, or 5; R4 and R5 are each independently H; (C1-C6alkoxy)carbonyl; C1-C6alkyl; Ce-Cnaryl, optionally substituted with R7R8NC(O)-, R7R8NC(O)NH-, CO2H, -CONH2, -CN, -NO2, R7R8N-, R7R8N-C,- C6alkylene, R7R8N-C1-C6alkylene-O-, R7R8N-C1-C6alkylene-NH-, R7R8N-NH-, C1-C9heteroaryl, C1-C9heteroaryl-O-, C1-C9heterocyclyl-O-, C1-C6alkyl, C1-C6alkoxy, C1-C6hydroxylalkyl-, C1- C9heterocycle, wherein the ring portion of the C1-C9heterocycle group is optionally substituted by C1-C6alkyl, halogen, NH2-C1-C6alkylene-, (C1-C6alkyl)-NH-C1-C6alkylene-, (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-, or (C1-C6alkoxy)carbonyl; C1-C9heteroaryl, optionally substituted by R7R8C(O)-, R7R8NC(O)NH-, CO2H, -CONH2, -CN, -NO2, R7R8H R7R8N-C1-C6alkylene, R7R8N-C1-C6alkylene-O-, R7R8N-C1-C6alkylene-NH-, R7R8N-NH-, C1-C9heteroaryl, C1-C9heteroaryl-O-, C1-C9heterocyclyl-O-, C1-C6alkyl, C1-C6alkoxy, C1-C6hydroxylalkyl-, C1-C9heterocycle, wherein the ring portion of the C1-C9heterocycle group is optionally substituted by C1-C6alkyl, halogen, NH2-C1-C6alkylene-, (C1-C6alkyl)-NH-C1-C6alkylene-, (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-, or (C1-C6alkoxy)carbonyl-; C1-C9heterocycle optionally substituted by (C6-C14aryl)alkyl-OC(O)- or C1-C6alkyl; C3-C8cycloalkyl; heterocyclyl(C1-C6alkyl) optionally substituted with C1-C6alkyl; C1-C6alkyl-OC(O)N(C1-C3alkyl)C1-C6alkylene; NH2-C1-C6alkylene-; (C1-C6alkyl)-NH-C1-C6alkylene-; or (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-; or R4 and R5 when taken together with the nitrogen to which they are attached optionally form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle is optionally replaced with -N(H)-, -O-, or -S(O)p-; p is 0, 1 or 2; R6 is C1-C6alkyl; C6-C14aryl; (C6-C14aryl)alkyl, optionally substituted by NH2; or C1-C6perfluoroalkyl-; R7 and R8 are each independently H; C1-C6alkyl optionally substituted with C1-C6alkoxy; C1-C8acyl optionally substituted with NH2, (C1-C6alkyl)amino, or di(C1-C6alkyl)amino; (C1-C6alkyl)SO2- optionally substituted with NH2, (C1-C6alkyI)amino, or di(C1-C6alkyl)amino; (C1-C6alkyl)SO- optionally substituted with NH2, (C1-C6alkyl)amino, or di(C1-C6alkyl)amino; C6-C14aryl-; (C6-C14aryl)SO2-; (C6-C14aryl)SO-; aryl(C1-C6alkyl) optionally substituted with C1-C6alkoxy, C1-C6alkyl, or halo; C1-C9heteroaryl; (C1-C9heteroaryl)SO2-; (C1-C9heteroaryl)SO-; heterocyclylSO2-; heterocyclylSO-; C1-C6hydroxylalkyl; heteroaryl(C1-C6alkyl) optionally substituted with C1-C6alkoxy, C1-C6alkyl, or halo; heterocyclyl(C1-C6alkyl) optionally substituted with C1-C6alkyl; C1-C9heterocycle optionally substituted by (C6-C14aryl)alkyl-OC(O)-; NH2-C1-C6alkylene-; (C1-C6alkyl)-NH-C1-C6alkylene-; or (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-; or R7 and R8 when taken together with the nitrogen to which they are attached optionally form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle are optionally replaced with -N(R9)-, -O-, or -S(O)q-, and wherein the heterocycle is optionally substituted with from 1 to 3 substituents independently selected from C1-C6alkyl; (C1- C6alkyl)amino-, C6-C14aryl, di(C1-C6alkyl)amino-, H2N-, C1-C9heteroaryl, and C1-C9heterocycle; q is 0, 1 or 2; R9 is H or C1-C6alkyl; R3 is: (a) hydrogen; (b) C1-C6alkyl optionally substituted with from 1 to 3 substituents independently selected from: (i) C1-C6alkoxy, (ii) NH2, (iii) (C1-C6alkyl)amino, (iv) di(C1-C6alkyl)amino, (v) CO2H, (vi) and (C1-C6alkoxy)carbonyl; (c) carboxyamidoalkyl optionally substituted with a substituent selected from: (i) halogen, (ii) and di(C1-C6alkyl)amino; (d) C1-C6perfluoroalkyl-; (e) C3-C8cycloalkyl; (f) C6-C14aryl optionally substituted with a substituent selected from: (i) -O-C1-C6alkylene-NH2, (ii) -COOH, (iii) C1-C6hydroxylalkyl, (iv) R10R11NC(O)-, (v) and (C1-C6alkoxy)carbonyl; (g) monocyclic C1-C6heterocycle optionally substituted with from 1 to 3 substituents independently selected from: (i) C1-C8acyl, wherein the C1-C8acyl is optionally substituted with a NH2, (ii) C1-C6alkyl, (iii) heteroaryl(C1-C6alkyl) wherein the ring portion of the heteroaryl(C1-C6alkyl) group is optionally substituted with from 1 to 3 substituents independently selected from: A) C1-C6alkylC(O)NH-, B) halogen, C) NH2, D) and C1-C6 alkyl, (iv) heterocyclyl(C1-C6alkyl), wherein the ring portion of the heterocyclyl(C1-C6alkyl) group is optionally substituted by a (C6-C14aryl)alkyl, (v) (C6-C14aryl)alkyl, wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by 1 to 3 substituents independently selected from: A) halogen, B) C1-C6alkyl, C) di(C1-C6alkyl)amino-(C1-C6alkylene)-O-, D) and C1-C9heteroaryl; (vi) and (C1-C6alkoxy)carbonyl; (h) heterocyclyl(C1-C6alkyl) optionally substituted with a substituent selected from: (i) C1-C6alkyl, (ii) C3-C8cycloalkyl, (iii) (C1-C6alkoxy)carbonyl, (iv) C1-C6alkylcarboxy, (v) (C6-C14aryl)alkyl wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by a: A) halogen, B) C1-C9heteroaryl, C) or di(C1-C6alkyl)amino-(C1-C6alkylene)-O-, (vi) heteroaryl(C1-C6alkyl) wherein the ring portion of the heteroaryl(C1-C6alkyl) group is optionally substituted by a halogen, (vii) and C1-C8acyl, wherein the C1-C8acyl is optionally substituted with from 1 to 3 independently selected halogens, (i) (C1-C6alkyl)-C(O)-NH-(C1-C6alkylene)-; (j) heteroaryl(C1-C6alkyl); (k) (C6-C14aryl)alkyl wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by a: (i) ClC6H4C(O)NH-, (ii) (C1-C6alkoxy)carbonyl, (iii) C02H, (iv) orR10RnNC(O); (1) C1-C6hydroxylalkyl; (m)or C1-C9heteroaryl; R10 and R11 are each independently: (a)H; (b) C1-C6alkyl optionally substituted with a substituent selected from: (i) C1-C6alkylC(O)NH-, (ii) NH2, (iii) (C1-C6alkyl)amino, (iv) or di(C1-C6alkyl)amino, (c) C3-C8cycloalkyl; (d) C6-C14aryl optionally substituted with a substituent selected from: (v) halogen, (vi) and monocyclic C1-C6heterocycle wherein the monocyclic C1-C6heterocycle is optionally substituted with (C1-C6alkoxy)carbonyI; (n) C1-C9heteroaryl; (o) heteroaryl(C1-C6alkyl); (p) heterocyclyl(C1-C6alkyl); (q) (C6-C14aryl)alkyl, wherein the chain portion of the (C6-C14aryl)alkyl group is optionally substituted by a hydroxyl; (r) or monocyclic C1-C6heterocycle optionally substituted with a (C1-C6alkoxy)carbonyl; or R10 and R11 when taken together with the nitrogen to which they are attached optionally form a 3- to 7- membered nitrogen-containing heterocycle wherein up to two of the carbon atoms of the heterocycle are optionally replaced with -N(H)-, -N(C1-C6alkyl)-, -N(C6-C14aryl)-, or -O-, and wherein the nitrogen-containing heterocycle is optionally substituted by a C1-C6alkyl; C6-C14aryl (C1-C6alkoxy)C(O)NH-, or C1-C9heterocycle. R4 and R5 are suitably each independently H; (C1-C6alkoxy)carbonyl; C1-C6alkyl; C6-C14aryl, optionally substituted with halogen, R7R8NC(O)-, CO2H, -CONH2, -CN, R7R8N, R7R8N-C1-C6alkylene, R7R8N-C1-C6alkylene-O-, R7R8N-C1-C6alkylene-NH-, R7R8N-NH-, C1-C9heteroaryl, C1-C9heteroaryl-O-, heterocyclyl, heterocyclyl-O-, C1-C6alkyl, C1-C6alkoxy, C1-C6hydroxylalkyl-, C1-C9heterocycle, wherein the ring portion of the C1-C9heterocycle group in turn is optionally substituted by C1-C6alkyl, halogen, NH2-C1-C6alkylene-, (C1-C6alkyl)-NH-C1-C6alkylene-, (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-, or (C1-C6alkoxy)carbonyl; C1-C9heteroaryl, optionally substituted by C1-C6alkyl R7R8N-C1-C6alkylene, R7R8N-C1-C6alkylene-O-, R7R8N-C1-C6alkylene-NH-, R7R8N-NH-, C1-C9heteroaryl, C1-C9heteroaryl-O-, heterocyclyl, or heterocyclyl-O-; C1-C9heterocycle optionally substituted by (C6-C14aryl)alkyl-OC(O)- or C1-C6alkyl; C3-C8cycloalkyl; heterocyclyl(C1-C6alkyl) optionally substituted with C1-C6alkyl; C1-C6alkyl-OC(O)N(C1-C3alkyl)C1-C6alkylene; NH2-C1-C6alkylene-; (C1-C6alkyl)-NH-C1-C6alkylene-; or (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-. R7 and R8 are suitably each independently H; C1-C6alkyl; C1-C8acyl optionally substituted with NH2, (C1-C6alkyl)amino, or di(C1-C6alkyl)amino; (C1-C6alkyl)SO2- optionally substituted with NH2, (C1-C6alkyl)amino, or di(C1-C6alkyl)amino; (C1-C6alkyl)SO- optionally substituted with NH2, (C1-C6alkyl)amino, or di(C1-C6alkyl)amino; (C6-C14aryl)SO2-; (C6-C14aryl)SO-; (C1-C9heteroaryl)SO2-; (C1-C9heteroaryl)SO-; heterocyclylSO2-; heterocyclylSO-; C1-C6hydroxylalkyl; heteroaryl(C1-C6alkyl) optionally substituted with C1-C6alkyl; heterocyclyl(C1-C6alkyl) optionally substituted with C1-Cealkyl; C1-C9heterocycle optionally substituted by (C6-C14aryl)alkyl-OC(O)-; NH2-C1-C6alkylene-; (C1-C6alkyl)-NH-C1-C6alkylene-; orC1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-. R7 and R8 when taken together with the nitrogen to which they are attached suitably form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle are optionally replaced with -N(R9)-, -O-, or -S(O)q-, and wherein the heterocycle is optionally substituted with from 1 to 3 substituents independently selected from C1-C6alkyl; C6-C14aryl, C1-C9heteroaryl, and C1-C9heterocycle. In certain embodiments n is 0. In certain embodiments A is -O-. In certain embodiments r is 1. Ar may suitably representa nitrogen-containing monocyclic heteroaryl. Ar may suitably represent pyridinyl. Ar may represent 3-pyridinyl. In certain embodiments Ar may represent phenyl. Ar may suitably represent phenyl substituted in the 4-position by R2, where R2 may suitably behydroxyl or -NHC(O)NR4R5. R3 may suitably be C1-C6alkylor ethyl. In certain embodiments R4 is C6-C14aryl, optionally substituted with R7R8NC(O)-; R4 may suitably be phenyl, substituted with R7R8NC(O)-, e.g. phenyl, substituted in the 4-position with R7R8NC(O)-. In certain embodiments R5 is H. In certain embodiments R7 is (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-. R7 may suitably be 2-(dimethylamino)ethyl. In certain embodiments R8 is H. In certain embodiments R7 and R8 taken together with the nitrogen to which they are attached form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle are optionally replaced with -N(R9)-, -O-, or -S(O)q-. R7 and R8 may suitably betaken together with the nitrogen to which they are attached form a 6- membered nitrogen containing heterocycle wherein one of the carbon atoms of the heterocycle is replaced with -N(R9)-, e.g. R7 and R8 taken together are 4-methylpiperazin-l-yl. R9may suitably be C1-C6 alkyl. In certain embodiments R3 is a monocyclic C1-C6heterocycle optionally substituted with from 1 to 3 substituents independently selected from C1-C8acyl, C1-C6alkyl, heterocyclyl(C1-C6alkyl), wherein the ring portion of the heterocyclyl(C1-C6alkyl) group is optionally substituted by 1 to 3 substituents independently selected from halogen, -NH2, -O(C1-C6alkyl), C1-C6alkyl, monocyclic C1-C6heterocycle, (C6-C14aryl)alkyl, and C3-C8cycloalkyl, (C6-C14aryl)alkyl, wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by 1 to 3 substituents independently selected from halogen, -NH2, -O(C1-C6alkyl), C1-C6alkyl, monocyclic C1-C6heterocycle, and C3-C8cycloalkyl. In particular embodiments R3 is a piperidinyl group optionally substituted with from 1 to 3 substituents independently selected from C1-C8acyl, C1-C6alkyl, heterocyclyl(C1-C6alkyl), wherein the ring portion of the heterocyclyl(C1-C6alkyl) group is optionally substituted by 1 to 3 substituents independently selected from halogen, -NH2, -O(C1-C6alkyl), C1-C6alkyl, monocyclic C1-C6heterocycle, (C6-C14aryl,alkyl, and C3-C8cycloalkyl, (C6-C14aryl)alkyl, wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by 1 to 3 substituents independently selected from halogen, -NH2, -O(C1-C6alkyl), C1-C6alkyl, monocyclic C1-C6heterocycle, and C3-C8cycloalkyl. R3 may suitably be a piperidin-4-yl group optionally substituted with from 1 to 3 substituents independently selected from C1-C8acyl, C1-C6alkyl, heterocyclyl(C1-C6alkyl), wherein the ring portion of the heterocyclyl(C1-C6alkyl) group is optionally substituted by 1 to 3 substituents independently selected from halogen, -NH2, -O(C1-C6alkyl), C1-C6alkyl, monocyclic C1-C6heterocycle, (C6-C14aryl)alkyl, and C3-C8cycloalkyl, (C6-C14aryl)alkyl, wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by 1 to 3 substituents independently selected from halogen, -NH2, -O(C1-C6alkyl), C1-C6alkyl, monocyclic C1-C6heterocycle, and C3-C8cycloalkyl. R3 may suitably bea piperidinyl group substituted with from 1 to 3 substituents independently selected from heterocyclyl(C1-C6alkyl), wherein the ring portion of the heterocyclyl(C1-C6alkyl) group is optionally substituted by 1 to 3 substituents independently selected from halogen, and C1-C6alkyl, and (C6-C14aryl)alkyl wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by 1 to 3 halogens. R3 may suitably be a piperidinyl group substituted with heterocyclyl(C1-C6alkyl), wherein the ring portion of the heterocyclyl(C1-C6alkyl) group is optionally substituted by 1 to 3 substituents independently selected from halogen, -and C1-C6alkyl. or R3 may suitably be a piperidinyl group substituted with (C6-C14aryl)alkyl wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by 1 to 3 halogens. In one aspect, n is 0, A is -O-, r is 1, Ar is 3-pyridinyl, R2 is hydroxyl, and R3 is a 4-piperidinyl group substituted with from 1 to 3 substituents independently selected from heterocyclyl(C1-C6alkyl), wherein the ring portion of the heterocyclyl(C1-C6alkyl) group is optionally substituted by 1 to 3 substituents independently selected from halogen, or C1-C6alkyl, and (C6-C14aryl)alkyl wherein the ring portion of the (C6-C14aryi)alkyl group is optionally substituted by 1 to 3 halogens. In one aspect, n is 0, A is -O-, r is 1, Ar is 3-pyridinyl, R2 is hydroxyl, and R3 is a 4-piperidinyl group substituted with pyridylmethyl, wherein the ring portion of the pyridylmethyl group is by halogen. In one aspect, n is 0, A is -O-, r is 1, Ar is 3-pyridinyl, R2 is hydroxyl, and R3 is a 4-piperidinyl group substituted with benzyl, wherein the ring portion of the benzyl group is optionally substituted by 1 to 3 halogens. In one aspect, n is 0, A is -O-, r is 1, Ar is phenyl, R2 is -NHC(O)NR4R5, R4 is C6-C14aryl, optionally substituted with R7R8NC(O)-, and R3 is C1-C6alkyl. In one aspect, n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R5 is H, and R3 is ethyl. In one aspect, n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 is (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-, R8 is H, R5 is H, and R3 is ethyl. In one aspect, n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 is 2-(dimethylamino)ethyl, R8 is H, R5 is H, and R3 is ethyl. In one aspect, n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 and R8 taken together with the nitrogen to which they are attached form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle optionally are replaced with -N(R9)-, -O-, or -S(O)q-, R5 is H, and R3 is ethyl. In one aspect, n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 and R8 taken together with the nitrogen to which they are attached form a 6- membered nitrogen containing heterocycle wherein one of the carbon atoms of the heterocycle is replaced with -N(R9)-, R5 is H, and R3 is ethyl. In one aspect, n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5 R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 and R5 taken together with the nitrogen to which they are attached form a 6- membered nitrogen containing heterocycle wherein one of the carbon atoms of the heterocycle is replaced with -N(R9)-, R9 is C1-C6alkyl, R5 is H, and R3 is ethyl. In one aspect, n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 and R8 taken together with the nitrogen to which they are attached form a 6- membered nitrogen containing heterocycle wherein one of the carbon atoms of the heterocycle is replaced with -N(R9)-, R9 is methyl, R5 is H, and R3 is ethyl. Illustrative compounds of Formula 1 include by the following compounds: 3-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 5-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyrimidin-2-amine; 5-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin-3-ol; l-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl} -3 -[2 -(dimethyl amino)ethyl] urea; N- {4-[3-( 1 -benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-2,2,2-trifiuoroacetamide; l-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-methylurea; N-{2-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]ethyl}acetamide; N-(2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl}ethyl)acetamide; 3-[7-morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; {3-[7-morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl} methanol; 5-(lH-indazol-4-yl)-7-morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine; 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-{3-[ 1 -(2-furylmethyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[ 1,2,3]triazoio[4,5-d]pyrimidin-5- yl}pyridin-3-ol: 5-{3-[l-(4-fluoroben2yl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}pyridin-3-ol; 5-(3-{l-[(6-bromopyridin-3-yl)methyl]piperidin-4-yI}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)pyridin-3 -ol; 5-(3-{l-[(5-bromopyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)pyridin-3-ol; 5-[3-(l-{4-[3-(dimethylamino)propoxy]benzyl}piperidin-4-yl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin-3-ol; 5-{3-[1-(3,4-difluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5- d]pyrimidin-5-yl} pyridin-3-ol; 5-(3-{1-[(1 -methyl-1H-pyrrol-2-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-(3-{l-[(6-chloropyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)pyridin-3-ol; 5-(3-{l-[(5-methyl-2-thienyl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)pyridin-3-ol; 5-[3-(l-rnethylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin- 3-ol; 5-{3-[l-(2,4-difluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}pyridin-3-ol; 5-(3-{l-[(l-methyl-lH-imidazol-5-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; N-[3-({4-[5-(5-hydroxypyridin-3-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]piperidin-l-yl}methyl)pyridin-2-yl]-2,2-dimethylpropanamide; 5-(3-{l-[(4,5-dimethyl-2-thienyl)methyl]piperidin-4-yI}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-[3-(l-butylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin- 3-ol; 5-(3- {1-[(4-benzy Ipiperazin-1-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-{7-morpholin-4-yl-3-[l-(lH-pyiTol-2-ylmethyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5 -yl} pyridin-3-ol; 5-(3-{l-[(l-methyl-lH-pyrazol-5-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-{7-morpholin-4-yl-3-[l-(4-pyridin-4-ylbenzyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}pyridin-3-ol; 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline; l-[4-(3-ethyl'7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-4- ylurea; 1-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 5-yl)phenyl]urea; 1-[4-(3-ethyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2- methylpyridin-4-yl)urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4H-l,2,4- triazol-4-yl)urea; l-[4-(3-ethyl-7-morpholin-4-yI-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(l,3-thiazol- 2-yl)urea; 2-(4-aminophenyl)ethyl [4-(3-ethyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamate; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-3- ylurea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2- thienyl)urea; methyl 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl] carbamoyl} amino)benzoate; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzoic acid; N-[2-(dimethylamino)ethyl]-4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide; 1-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4- methylpiperazin-1-yl)carbonyl]phenyl} urea; N-[2-(dimethylamino)ethyl]-4-({[4-(3-ethyl-7-morpholm-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]carbamoyl}amino)-N-methylbenzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(2-hydroxyethyl)benzamide; N-[3-(dimethylamino)propyl]-4-({ [4-(3-ethyl-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4- morpholin-4-ylpiperidin-1 -yl)carbonyl]phenyl} urea; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-[2-(4-methylpiperazin-l-yl)ethyI]benzamide; 1-[4-( 1,4'-bipiperidin-1'-ylcarbonyl)phenyl]-3-[4-(3-ethyl-7-morpholin-4-yl-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyI]urea; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(pyridin-4-ylmethyl)benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-methyl-N-[2-(rnethylamino)ethyl]benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(2-morpholin-4-ylethyl)benzamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(3R)-3- methylpiperazin-l-yl]carbonyl}phenyl)urea; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-[3-(4-methylpiperazin-l-yl)propyl]benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(2-piperidin-1-ylethyl)benzamide; l-{4-[(3,3-dimethylpiperazin-l-yl)carbonyl]phenyl}-3-[4-(3-ethyl-7-morpholin-4-yl-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; I-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4- pyridin-2-ylpiperazin-1-yl)carbonyl]phenyl} urea; 4-({[4-(3-ethyI-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-[(l-ethylpyrrolidin-2-yl)methyl]benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2J3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N,N-dimethylbenzamide; N-butyl-4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(2-pyridin-2-ylethyl)benzamide; N-ethyl-4-({[4-(3-ethyI-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzamide; benzyl 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)piperidine-l-carboxylate; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-piperidin-4- ylurea; 4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}aniline; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-[4-(2-hydroxyethyl)phenyl]urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-(2-thienyl)urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-[4-(hydroxymethyl)phenyl]urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yI]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-pyridin-4-ylurea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-pyridin-3-ylurea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-(4-methoxyphenyl)urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-(4-fluorophenyl)urea; -(4-cyanophenyl)-3-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenyl)urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-[4-(4-methylpiperazin-l-yl)phenyl]urea; 4-(3-cyclopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline; l-[4-(3-cyclopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- pyridin-4-ylurea; l-[4-(3-cyclopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- pyridin-4-ylurea; l-[4-(3-cyclopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2- thienyl)urea; 4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin- 4-ylurea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin- 3-ylurea; l-[4-(hydroxymethyl)phenyl]-3-[4-(3-isopropyl-7-morphoIin-4-yl-3H-[l,2,3]triazo!o[4,5- d]pyrimidin-5-yl)phenyl]urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4- morpholin-4-ylphenyl)urea; l-[4-(dimethylamino)phenyl]-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4J5- d]pyrimidin-5-yl)phenyl]urea; l-(4-fluorophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazoIo[4,5-d]pyrimidin-5- yl)phenyl]urea; l-[2-(dimethylamino)ethyl]-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4- methoxyphenyl)urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4- methylphenyl)urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- methylurea; l-[(l-ethylpyrrolidin-2-yl)methyl]-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]urea; 4-({[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzamide; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-isoxazol- 4-ylurea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(lH- pyrrol-3-yl)urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; tert-butyl 4-{2-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3- yl]ethyl}piperazine-l-carboxyIate; 3-[7-morpholin-4-yl-3-(2-piperazin-l-ylethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-{3-[2-(4-benzoylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-{7-morpholin-4-yl-3-[2-(4-propionylpiperazin-l-yl)ethyl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 5-yl}phenol; 3-(3-{2-[4-(4-fluorobenzoyl)piperazin-l-yl]ethyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-(3-{2-[4-(3,4-difluorobenzoyl)piperazin-l-yl]ethyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-{3-[2-(4-isonicotinoylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenol; 3-(7-morpholin-4-yl-3-{2-[4-(phenylacetyl)piperazin-l-yl]ethyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-{3-[2-(4-acetylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-{3-[2-(4-cyclohexylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenol; 3-{3-[2-(4-butylpiperazin-1-yl)ethyl]-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimiclin-5- yl}phenol; 3-{3-[2-(4-isobutylpiperazin-l-yl)ethyi]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-(3-{2-[4-(3-fluorobenzyl)piperazin-l-yl]ethyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-{3-[2-(4-{4-[3-(dimethylamino)propoxy]benzyl}piperazin-l-yl)ethyl]-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenol; 3-(7-morpholin-4-yl-3- {2-[4-(pyridin-3 -ylmethyl)piperazin-1 -yl]ethyl}-3H-[1,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-(7-morpholin-4-yl-3-{2-[4-(lH-pyrrol-2-ylmethyl)piperazin-l-yl]ethyl}-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenol; 3-(3-{2-[4-(2-furylmethyl)piperazin-l-yl]ethyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-{3-[2-(4-benzylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; methyl 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]benzoate; methyl 3-[5-(3-formylphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]benzoate; [(7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine-3,5-diyl)di-3,l-phenylene]dimethanol; 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzoic acid; 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzamide; 3-(7-morpholin-4-yl-3-{3-[(4-pyrrolidin-l-ylpiperidin-l-yl)carbonyl]phenyl}-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenol; 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]-N- methylbenzamide; N-[2-(dimethylamino)ethyl]-3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]benzamide; 3-(7-morpholin-4-yl-5-{4-[(phenylcarbamoyl)amino]phenyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)benzoic acid; tert-butyl 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-3- yl]azetidine-1 -carboxylate; 3-(3-azetidin-3-yl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenol; 3-{3-[l-(2-aminobenzoyl)azetidin-3-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-[3-(l-benzylazetidin-3-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-(3-{l-[(6-fluoropyridin-3-yl)methyl]azetidin-3-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; (llbS)-l 1,1 lb-dimethyl-2,3,5,6,11,1 lb-hexahydro-lH-indolizino[8,7-b]indol-8-ol; diethyl 8-ethynyl-7-hydroxydibenzo[b,d]furan-3,4-dicarboxylate; tert-butyl 3-(7-morpholin-4-yl-5-{4-[(phenylcarbamoyl)amino]phenyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)azetidine-1 -carboxylate; tert-butyl 3-(7-morpholin-4-yl-5-{4-[(2-thienylcarbamoyl)amino]phenyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)azetidine-1 -carboxylate; 4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]aniline; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-pyridin-4-ylurea; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-pyridin-3-ylurea; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-pyrimidin-5-ylurea; l-[4-(dirnethylamino)phenyl]-3-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}urea; l-[4-(2-hydroxyethyl)phenyl]-3-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pheny]}urea; tert-butyl methyl{2-[({4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5 -yl]phenyl} carbamoyl)amino]ethyl} carbamate; l-[2-(methylamino)ethyl]-3-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}urea; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-(2-thienyl)urea; I-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3-(3 -thienyl)urea; tert-butyl4-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]piperidine-1 -carboxylate; 3-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenol; 3-{7-morpholin-4-yl-3-[l-(lH-pyrrol-2-ylmethyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenol; 3-[3-(l-{4-[3-(dimethylamino)propoxy]benzyl}piperidin-4-yl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-{3-[l-(4-fluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; tert-butyl4-[5-(2-aminopyrimidin-5-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]piperidine-1 -carboxylate; 3-{7-morpholin-4-yl-3-[l-(pyridin-2-ylmethyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenol; tert-butyl4-(7-morpholin-4-yl-5-{4-[(pyridin-3-ylcarbamoyl)amino]phenyl}-3H- [ 1,2,3]triazolo[4,5-d]pyrimidin-3-yl)piperidine-1 -carboxylate; tert-butyl4-{5-[4-({[2-(dimethyIamino)ethyl]carbamoyl}amino)phenyl]-7-morpholin-4-yI-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl}piperidine-l-carboxylate; l-[2-(dimethylamino)ethyl]-3-[4-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5 -yl)phenyl]urea; 1-[2-(dimethylamino)ethyl] -3 -(4- { 3 -[ 1 -(4-fluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; l-[2-(dimethylamino)ethyl]-3-(4-{7-morpholin-4-yl-3-[l-(pyridin-3-ylmethyl)piperidin-4-yl]- 3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; l-[4-(3-{l-[(6-bromopyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[2-(dimethylamino)ethyl]urea; l-(4-{3-[l-(4-chloro-2-fluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenyl)-3-[2-(dimethylamino)ethyl]urea; l-[2-(dimethylamino)ethyl]-3-[4-(3-{l-[(6-fluoropyridin-3-yl)methyl]piperidin-4-yl}-7- morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; l-[2-(dimethylamino)ethyl]-3-[4-(3-{l-[(5-methyl-2-thienyl)methyl]piperidin-4-yl}-7- morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5-yi)phenyl jurea; l-{4-[3-(l-butylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-[2-(dimethylamino)ethyl]urea; 1 -[2-(dimethylamino)ethyl]-3-(4-{7-morpholin-4-yl-3-[ 1 -(4-pyridin-4-ylbenzyl)piperidin-4-yl]- 3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; 1 -[2-(dimethylamino)ethyl]-3 -(4-{ 7-morpholin-4-yl-3-[ 1 -(1 H-pyrrol-2-ylmethyl)piperidin-4-yl]- 3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; l-[2-(dimethylamino)ethyl]-3-{4-[3-(l-{4-[3-(dimethylamino)propoxy]benzyl}piperidin-4-yl)-7- morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}urea; l-[4-(7-morphoIin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- pyridin-3-ylurea; l-{4-[3-(l-methylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3 -pyridin-3-y lurea; tert-butyl4-[5-(4-{[(4-fluorophenyl)carbamoyl]amino}phenyl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl]piperidine-l-carboxylate; tert-butyl4-(7-morpholin-4-yl-5-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl)piperidine-l-carboxylate; l-[4-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- pyridin-4-ylurea; tert-butyl4-(5-{4-[(methylcarbamoyl)amino]phenyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yI)piperidine-1 -carboxylate; tert-butyl4-[5-(4-{[(methoxycarbonyl)carbamoyl]amino}phenyl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl]piperidine-l-carboxylate; l-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-(3-chlorophenyl)urea; 5-(3-{l-[(2-amino-l,3-thiazol-5-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 3-{3-[(l -ethylpyrrolidin-2-yl)methyl]-7-morpholin-4-yl-3H-[l ,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; {5-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]pyridin-3-yl} methanol; [5-(7-morpholin-4-yl-3-piperidm-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3- yl]methanol; 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)-2-methoxyaniline; [3-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]methanol; {3-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} methanol; 4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]aniline; l-{4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3 -(4 -methylphenyl)urea; l-{4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yI]phenyl}-3-(4-fluorophenyl)urea; l-{4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-pyridin-3-ylurea; 4-[({4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}carbamoyl)amino]benzamide; l-{4-[3-(2-hydroxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- pyridin-4-ylurea; l-{4-[3-(2-hydroxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- pyridin-3-ylurea; l-{4-[3-(2-hydroxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- (4-methoxyphenyl)urea; l-{4-[3-(2-hydroxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- phenylurea; tert-butyl 3-{[5-(4-aminophenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}azetidine-l-carboxylate; tert-butyl 3-[(7-morpholin-4-yl-5-{4-[(phenylcarbamoyl)amino]phenyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)methyl]azetidine-l -carboxylate; l-{4-[3-(azetidin-3-ylmethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3 -phenylurea; -(4-{3-[(l-benzoylazetidin-3-yl)methyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)-3-phenylurea; l-(4-{3-[(l-benzylazetidin-3-yl)methyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)-3-phenylurea; l-[4-(3-{[l-(4-fluorobenzyl)azetidin-3-yl]methyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-phenylurea; l-[4-(7-morpholin-4-yl-3-{[l-(4-pyriuai-4-ylbenzyl)azetidin-3-yl]methyl}-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-phenylurea; l-(4-{3-[(l-{4-[3-(dimethylamino)propoxy]benzyl}azetidin-3-yl)methyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)-3-phenylurea; 3-[7-morpholin-4-yl-3-(2-piperidin-l-ylethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-[7-morpholin-4-yl-3-(2-pyridin-2-ylethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 4-chloro-N-(4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}phenyl)benzamide; l-{4-[7-morpholin-4-yl-3-(tetrahydro-2H-pyran-4-yl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-pyridin-4-ylurea; l-[4-(3-methyl-7-morpholin-4-yl-3H-[lJ2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea; l-[4-(3-methyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2-thienyl)urea; l-[4-(3-methyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(3-thienyl)urea; 3-{3-[4-(dimethylamino)butyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenol; 3-{3-[4-(methylamino)butyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenol; 3-[3-(4-aminobutyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-[7-morpholin-4-yl-3-(4-pyrrolidin-l-ylbutyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-{3-[4-(4-benzylpiperazin-l-yl)butyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenol; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N-methylbenzamide; xert-butyl 4-[(4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}benzoyl)amino]piperidine-i-carboxyiate; tert-butyl[l-(4-{[5-(3-hydroxyphenyl)-7-morphoIin-yl-3T141,23]triazolo[4,5-d]pyrimidin-3- yl]methyl} benzoyl)piperidin-4-yl]carbamate; N-(2-acetamidoethyl)-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl}benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]tnazolo[4,5-d]pyrimidin-3-yl]methyl}-N- (3-pyrrolidin-1 -ylpropyl)benzamide; N-benzyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- (2-pyrrolidin-1 -ylethyl)benzamide; N-[2-(dimethylamino)ethyl]-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl}benzamide; N-[3-(dimethylamino)propyl]-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- pyridin-3-ylbenzamide; N-(4-fluorophenyl)-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl}benzamide; tert-butyl4-{4-[(4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 3-yl]methyl} benzoyl)amino]phenyl }piperazine-1 -carboxylate; N-ethyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yljmethyl} benzamide; N,N-diethyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl] methyl} benzamide; N-cyclopropyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl] methyl} benzamide; N-tert-butyl-4-{ [5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- (2-pheny lethy l)benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- [(1S)-1 -phenylethyl]benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- [2-(lH-indol-3-yl)ethyl]benzamide; N-(2-hydroxy-2-phenylethyl)-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d] pyrimidin-3 -yl] methyl} benzamide; 3-{7-morpholin-4-yl-3-[4-(piperidin-l-ylcarbonyl)benzyl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-{7-morpholin-4-yl-3-[4-(pyrrolidin-l-ylcarbonyl)benzyl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 5-yl}phenol; 3-(7-morpholin-4-yl-3 - {4-[(4-phenylpiperazin-1 -yl)carbonyl]benzyl} -3H- [ 1,2,3]triazolo[4,5 - d]pyrimidin-5-yl)phenol; N-(2-furylmethyl)-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl}benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-tl,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- [2-(lH-imidazol-5-yl)ethyl]benzamide; tert-butyl {5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 3-yl} acetate; tert-butyl [5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]acetate; tert-butyl (7-morpholin-4-yl-5-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl)acetate; 2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl}-N- pyridin-3-ylacetamide; 2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl}-N- methylacetamide; 2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl}acetamide; N-(4-fluorophenyl)-2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,253]triazolo[4,5- d]pyrimidin-3 -yl} acetamide; N-[2-(dimethylamino)ethyl]-2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl}acetamide; {5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl}acetic acid; methyl 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3- yl] methyl} benzoate; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}benzoic acid; methyl 4-({5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 3-yl} methyl)benzoate; methyl 4-{[5-(3-fluoro-5-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 3-yl] methyl} benzoate; and [5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]aceticacid. Illustrative compounds of Formula 1 include the following compounds: l-{4-[(2,2-dimethylhydrazino)carbonyl]phenyl}-3-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-nitrophenyl)urea; l-(4-aminophenyl)-3-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]-N2,N2-dimethylglycinamide; 3-[5-(4-{[(4-{[2-(dimethylamino)ethyl]carbamoyl}phenyl)carbamoyl]amino}phenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzoicacid; 4-[({4-[3-(3-carbamoylphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}carbamoyl)amino]-N-[2-(dimethylamino)ethyl]benzamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(pyridin-4-ylmethyl)amino]phenyl} urea; I-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(pyridin- 3-ylmethyl)amino]phenyi} urea; I-[4-(3-ethyl-7-morpholin-4-yI-3H-[l,2,3]triazolo[4,5-d]p>Timidin-5-yl)phenyl]-3-(4-{[(6- fluoropyridin-3-yl)methyl]amino}phenyl)urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(6- methoxypyridin-3-yl)methyl]amino}phenyl)urea; N-[2-(dimethylamino)ethyl]-4-[({4-[3-(l-rnethylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl]phenyl}carbamoyl)amino]benzamide; l-{4-[3-(l-methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- {4-[(4-methylpiperazin-l-yl)carbonyl]phenyl}urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4- methylpiperazin-1-yl)methy l]pheny]} urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-(4- methylpiperazin-1-yl)phenyl]urea; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-pyridin-3-yIbenzamide; N-[4-({[4-(3-ethyl-7-morpholin-4-yI-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]-4-methylpiperazine-l-carboxamide; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]pyridine-4-carboxamide; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]morpholine-4-carboxamide; 3-(dimethylamino)-N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]benzamide; l-[2-(dimethylamino)ethyl]-3-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl] carbamoyl} amino)phenyl] urea; 4-(dimethylamino)-N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]piperidine-l-carboxamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(l- methylpiperidin-4-yl)carbamoyl]amino}phenyl)urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl]-3-[4-({[2-(4- methylpiperazin-1-yl)ethyl]carbamoyl} amino)phenyl]urea; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl} amino)phenyl]-4-methyl-1,4-diazepane-1 -carboxamide; l-[2-(dimethylamino)ethyl]-3-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]-l-methylurea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(2- pyrrolidin-1 -ylethyl)carbamoyl]amino}phenyl)urea; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]-4-pyrrolidin-l-ylpiperidine-l-carboxamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(pyridin- 2-ylmethyl)carbamoyl]amino}phenyl)urea; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]piperazine-l-carboxamide; 4-ethyl-N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]piperazine-1 -carboxamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(2- methoxyethyl)carbamoyl]amino}phenyl)urea; l-{4-[3-(l-methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-[4- (4-methylpiperazin-1 -yl)phenyl]urea; l-{4-[3-(l-methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-(4- nitrophenyl)urea; N-[4-({[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]methanesulfonamide; l-(4-aminophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]urea; 1-(4- {[4-(dimethylamino)piperidin-1 -yl]carbonyl} phenyl)-3-(4- {3 -ethyl-7-[(3 S)-3 - methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3 - { 4- [(4-methylpiperazin-1 -yl)carbonyl]pheny 1} urea; 4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl }phenyi)carbamoyi jamino} -N-(2-pyrrolidin-1 -ylethyl)benzamide; 4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl }phenyl)carbamoyl]amino}-N-(2-piperidin-1-ylethyl)benzamide; N-[2-(dimethylamino)ethyl]-4- {[(4- {3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}-N-methylbenzamide; N-[2-(dimethylamino)ethyl]-4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[1,2,3]triazolo[4,5 -d]pyrimidin-5-yI}phenyl)carbamoyl]amino} benzamide; methyl 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)pyridine-2-carboxylate; 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)pyridine-2-carboxylic acid; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{6-[(4-methylpiperazin-1 -yl)carbonyl]pyridin-3 -yl }urea; and N-[2-(dimethylamino)ethyl]-5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)-N-methylpyridine-2-carboxamide. Illustrative compounds of Formula 1 include the following compounds: N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(3-methyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-4-(3-(4-(3-methyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)benzamide; l-(4-(3-methyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-3-(4-(4-methylpiperazine-1 -carbonyl)phenyl)urea; l-(4-(4-(dimethylamino)piperidine-l-carbonyl)phenyl)-3-(4-(3-methyl-7-morpholino-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea; N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(7-morpholino-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-4-(3-(4-(7-morpholino-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)benzamide; l-(4-(4-methylpiperazine-l-carbonyl)phenyl)-3-(4-(7-morpholino-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pheny!)urea; and 1 -(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)-3-(4-(7-morpholino-3-(2,2,2-trifluoroethyi)-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea. As some of the compounds of the present invention possess an asymmetric carbon atom in the morpholine ring, the present invention includes the racemate as well as the individual enantiomeric forms of the compounds of Formula 1 as described herein and in the claims. Mixtures of isomers of the compounds of the examples or chiral precursors thereof can be separated into individual isomers according to methods, which are known per se, e.g. fractional crystallization, adsorption chromatography or other suitable separation processes. Resulting racemates can be separated into antipodes in the usual manner after introduction of suitable salt-forming groupings, e.g. by forming a mixture of diastereosiomeric salts with optically active salt-forming agents, separating the mixture into diastereomeric salts and converting the separated salts into the free compounds. The enantiomeric forms may also be separated by fractionation through chiral high-pressure liquid chromatography columns. The invention also includes pharmaceutical compositions comprising an effective amount of a 3H-[l,2,3]triazolo[4,5-d]pyrimidine compound of Formula 1 and a pharmaceutically acceptable carrier. The compound may be provided as a pharmaceutically acceptable prodrug, hydrated salt, such as a pharmaceutically acceptable salt, or mixtures thereof. In another aspect, the invention provides methods of synthesizing compounds of the Formula 1 comprising: reacting a boronic acid of the formula (R2)r-Ar-B(OH)2 with the 5-halo-3H- [ 1,2,3]triazolo[4,5 -d]pyrimidine 2: (Formula Removed) wherein X is halo and A, Ar, Rl, n, R2, r, and R3, are as defined in Formula 1; (Formula Removed) thereby producing the 3H-[l,2,3]triazolo[4,5-d]pyrimidine 1. [0001] In one aspect, the invention provides methods of synthesizing compounds of the Formula 1 further comprising: (a) reacting the 2,4,6-trihalo-5-nitropyrimidine of Formula 3 with an amine 4 to substitute the halogen (Formula Removed) atom at position 4 of the pyrimidine (Formula Removed) thereby producing 5: (Formula Removed) (b) reacting dihalo pyrimidine 5 with amine R3-NH2 replacing the halogen atom at position 6 of the pyrimidine ring with radical R3-NH-; c) reducing the product of the proceeding reaction to convert the nitro group at position 5 of the pyrimidine ring to an amino group without removing the halogen atom at position 2 of the pyrimidine; d) diazotizing and cyclizing the diaminopyrimidine; (Formula Removed) thereby producing 3H-[l,2,3]triazolo[4,5-d]pyrimidine 2. Representative "pharmaceutically acceptable salts" include but are not limited to, e.g., water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (4,4'-methylenebis-3-hydroxy-2-naphthoate, or embonate), pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosaliculate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts. An "effective amount" when used in connection with a 3H-[l,2,3]triazolo[4,5-d]pyrimidine compound of this invention is an amount effective for inhibiting mTOR or PI3K in a subject. The following abbreviations are used herein and have the indicated definitions: ACN is acetonitrile, AcOH is acetic acid. ATP is adenosine triphosphate. BOC is t-butoxycarbonyl. Celite™ is flux-calcined diatomaceous earth. Celite™ is a registered trademark of World Minerals Inc. CHAPS is (3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonic acid, DEAD is diethyl azodicarboxylate, DIAD is diisopropylazodicarboxylate, DMAP is dimethyl aminopyridine, DME is 1,2-dimethoxyethane, DMF is N,N-dimethylformamide, DMF-DMA is dimethylformamide dimethyl acetal, and DMSO is dimethylsulfoxide. DPBS is Dulbecco's Phosphate Buffered Saline Formulation. EDCI is 3'-dimethylaminopropyl)carbodiimide or water-soluble carbodiimide, EDTA is ethylenediaminetetraacetic acid, ESI stands for Electrospray Ionization, EtOAc is ethyl acetate, and EtOH is ethanol. HBTU is O-benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate, HEPES is 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid, GMF is glass microfiber, HOBT is N-hydroxybenzotriazole, Hunig's Base is diisopropylethylamine, HPLC is high-pressure liquid chromatography, LPS is lipopolysaccharide. MeCN is acetonitrile, MeOH is methanol, MS is mass spectrometry, and NEt3 is triethylamine. Ni(Ra) is Raney™ nickel, a sponge-metal catalyst produced when a block of nickel-aluminum alloy is treated with concentrated sodium hydroxide. Raney™ is a registered trademark of W. R. Grace and Company. NMP is N-methylpyrrolidone, NMR is nuclear magnetic resonance, PBS is phosphate-buffered saline (pH 7.4), RPMI 1640 is a buffer (Sigma-Aldrich Corp., St. Louis, MO, USA), SDS is dodecyl sulfate (sodium salt), SRB is Sulforhodamine B, TCA is tricholoroacetic acid, TFA is trifluoroacetic acid, THF is tetrahydrofuran, THP is tetrahydro-2H-pyran-2-yl. TLC is thin-layer chromatography and TRIS is tris(hydroxymethyl)aminomethane. The following definitions are used in connection with the 3H-[l,2,3]triazolo[4,5-djpyrimidine compounds of the present invention, unless the context indicates otherwise. In general, the number of carbon atoms present in a given group is designated "Cx-Cv", where x and y are the lower and upper limits, respectively. For example, a group designated as "C1-Ce" contains from 1 to 6 carbon atoms. The carbon number as used in the definitions herein refers ts carbon backbone and carbon branching, but does not include carbon atoms of the substituents, such as alkoxy substitutions and the like. "Acyl" refers to a carbonyl group bonded to a moiety comprising from 1 to 8 carbon atoms in a straight, branched, or cyclic configuration or a combination thereof, attached to the parent structure through the carbonyl functionality. The moiety may be saturated or unsaturated, aliphatic or aromatic, and carbocyclic or heterocyclic. One or more carbons in the moiety may be replaced by oxygen, nitrogen (e.g., carboxyamido), or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples of C1-Cgacyl include acetyl-, benzoyl-, nicotinoyl, propionyl-, isobutyryl-, oxalyl-, t-butoxycarbonyl-, benzyloxycarbonyl, morpholinylcarbonyl, and the like. An acyl group can be unsubstituted or substituted with one or more, e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NHo, -NH(C1-C6alkyl), -N(C1-C6alkyl)(CrC6alkyl), -N(C,-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C,-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(Cr C6alkyl), C,-C6alkyl, -C(O)OH, -C(O)0(Cl,-C6alkyl), -C(O)(C1-C6alkyl), C6-Ci4aryl, Cr C9heteroaryl, or C3-Cscycloalkyl. "Alkenyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2-10 carbon atoms and at least one double bond. Examples of a C2-Cioalkenyl group include, but are not limited to, ethylene, propylene, 1-butylene, 2-butylene, isobutylene, sec-butylene, 1-pentene, 2-pentene, isopentene, 1-hexene, 2-hexene, 3-hexene, isohexene, 1-heptene, 2-heptene, 3-heptene, 1-octene, 2-octene, 3-octene, 4-octene, 1-nonene, 2-nonene, 3-nonene, 4-nonene, 1-decene, 2-decene, 3-decene, 4-decene and 5-decene. An alkenyl group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-C6alkyl), -NCQ-CealkylXC1-Qalkyl), -NCQ-CjalkyOCCOXC1-C6alkyl), -NHC(O)(d-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(d-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)0(d-C6alkyl), -C(O)(C,-C6alkyl), C6-C14aryl.C1-C9heteroaryl, and C3-C8cycloalkyl. "Alkoxy" refers to the group R-O- where R is an alkyl group, as defined below. Exemplary C1-C6alkoxy groups include but are not limited to methoxy, ethoxy, n-propoxy, 1- propoxy, n-butoxy and t-butoxy. An alkoxy group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen,, hydroxyl, CrC6alkoxy, -NH2, -NH(C,-C6alkyl), -N(C1-C6alkyl)(d-dalkylX -N(C,-C3alkyl)C(O)(C,-C6alkyl), -NHC(OXC1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(d-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, -O(C1-C6alkyl), -C(O)OH, -C(O)0(C1,-C6alkyl), -C(O)(C1-C6alkyl), d-Cary!, C1-C9heteroaryl, C3-C8cycloalkyl, haloalkyl-, aminoalkyl-, -OC(O)(C1-C6alkyl), C1-dcarboxyamidoalkyl-, or -NO2. "(Alkoxy)carbonyl" refers to the group alkyl-O-C(O)-. An (alkoxy)carbonyl group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, hydroxyl, -NH2, -NH(d-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -NCd-CaalkyOCCO)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(d-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, -O(C1-C6alkyl), -C(O)OH, -C(O)0(Cli-dalkyl), -C(O)(CrC6alkyl), d-Cnaryl, C1-Cgheteroaryl, C3-C8cycloalkyl, haloalkyl-, aminoalkyl-, -OC(O)(d-C6alkyl), C1-dcarboxyamidoalkyl-, or -N02. Exemplary (d-C6alkoxy)carbonyl groups include but are not limited to CH3-O-C(O)-, CH3CH2-O-C(O)-, CH3CH2CH2-O-C(O)-, (CH3)2CH-O-C(O)-, CH3CH2CH2CH2-O-C(O)-5 and t-butoxycarbonyl. "Alkyl" refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C1-C10 indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it. In the absence of any numerical designation, "alkyl" is a chain (straight or branched) having 1 to 6 (inclusive) carbon atoms in it. Examples of C1-C6 alkyl groups include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl. An alkyl group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-dalkyl), -N(d-C6alkyl)(d-dalkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-dalkyl, -C(O)OH, -C(O)O(C1-C6alkyl), -C(O)(C1-C6alkyl), C6-C14aryl; C1-C9heteroaryl, C3-C8cycloalkyl, haloalkyl-, aminoalkyl-, -OC(O)(C1-C6alkyl), C1-C6carboxyamidoalkyl-, or -NO2. "(Alkyl)amido-" refers to a -C(O)NH- group in which the nitrogen atom of said group is attached to an alkyl group, as defined above. Representative examples of a (C1-dalkyl)amido group include, but are not limited to, -C(O)NHCH3, -C(O)NHCH2CH3, -C(O)NHCH2CH2CH3) - C(O)NHCH2CH2CH2CH3, -C(O)NHCH2CH2CH2CH2CH3, -C(O)NHCH(CH3)2, C(O)NHCH2CH(CH3)2) -C(O)NHCH(CH3)CH2CH3, -C(O)NH-C(CH3)3 and C(O)NHCH2C(CH3)3. "(Alkyl)amino-" refers to an -NH group, the nitrogen atom of said group being attached to an alkyl group, as defined above. Representative examples of an (C1-C6alkyl)amino group include, but are not limited to -NHCH3, -NHCH2CH3, -NHCH2CH2CH3, -NHCH2CH2CH2CH3, -NHCH(CH3)2, -NHCH2CH(CH3) 2, -NHCH(CH3)CH2CH3 and -NH-C(CH3)3. An (alkyl)amino group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)O(Cl1-C6alkyl), -C(O)(C1-C6alkyl), C6-C14aryl, C1-C9heteroaryl, C3-C8cycloalkyl, haloalkyl-, aminoalkyl-, -OC(O)(C1-C6alkyl), C1-C6carboxyamidoalkyl-, or -NO2. "Alkylcarboxy" refers to an alkyl group as defined above, attached to the parent structure through the oxygen atom of a carboxyl (C(O)-O-) functionality. Examples of C1-C6alkylcarboxy include acetoxy, ethylcarboxy, propylcarboxy, and isopentylcarboxy. "(Alkyl)carboxyamido-" refers to a -NHC(O)- group in which the carbonyl carbon atom of said group is attached to an alkyl group, as defined above. Representative examples of a (Q-C6alkyl)carboxyamido group include, but are not limited to, -NHC(O)CH3, -NHC(O)CH2CH3, -NHC(O)CH2CH2CH3, -NHC(O)CH2CH2CH2CH3, -NHC(O)CH2CH2CH2CH2CH3, NHC(O)CH(CH3)2, -NHC(O)CH2CH(CH3)2, -NHC(O)CH(CH3)CH2CH3, -NHC(O)-C(CH3)3 and -NHC(O)CH2C(CH3)3. "Alkylene", "alkenylene", and "alkynylene" refers to the subsets of alkyl, alkenyl and alkynyl groups, as defined herein, including the same residues as alkyl, alkenyl, and alkynyl, but having two points of attachment within a chemical structure. Examples of C1-C6alkylene include methylene (-CH2-), ethylene (-CH2CH2-), propylene (-CH2CH2CH2-), and dimethylpropylene (-CH2C(CH3)2CH2-). Likewise, examples of C2-C6alkenylene include ethenylene (-CH=CH- and propenylene (-CH=CH—CH2-). Examples of C2-C6alkynylene include ethynylene (-C=C-) and propynylene (-C=C—CH2-). "Alkylthio" refers to groups of straight chain or branched chain with 1 to 6 carbon atoms, attached to the parent structure through a sulfur atom. Examples of a C1-C6alkylthio group include methylthio. ethylthio, n-propylthio, i-propylthio, n-butylthio, i-butylthio, s-butylthio, t-butylthio, n-pentylthio, and n-hexylthio. "Alkynyl" refers to a straight or branched chain unsaturated hydrocarbon containing 2-10 carbon atoms, respectively, and at least one triple bond. Examples of a C2-Cioalkynyl group include, but are not limited to, acetylene, propyne, 1-butyne, 2-butyne, isobutyne, sec-butyne, 1-pentyne, 2-pentyne, isopentyne, 1-hexyne, 2-hexyne, 3-hexyne, isohexyne, 1-heptyne, 2-heptyne, 3-heptyne, 1-octyne, 2-octyne, 3-octyne, 4-octyne, 1-nonyne, 2-nonyne, 3-nonyne, 4-nonyne, 1-decyne, 2-decyne, 3-decyne, 4-decyne and 5-decyne. A alkynyl group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(CrC6alkyl), -NCQ-CealkylXC1-Cealkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C,-C6alkyl), -C(O)N(Cr C6alkyl)(C,-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)0(C,-C6alkyl), -C(O)(C}-C6alkyl), C6-Ci4aryl, C1-C9heteroaryl, and C3-C8cycloalkyl. "Amido(aryl)-" refers to an aryl group, as defined below, wherein one of the aryl group's hydrogen atoms has been replaced with one or more -C(O)NH2 groups. Representative examples of an amido(C6-Ci4aryl)- group include 2-C(O)NH2 -phenyl, 3-C(O)NH2 -phenyl, 4-C(O)NH2 -phenyl, 1-C(O)NH2 -naphthyl, and 2-C(O)NH2 -naphthyl. "Amino(alkyl)-" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with -NH2. Representative examples of an amino(C1-C6alkyl) group include, but are not limited to -CH2NH2, -CH2CH2NH2, -CH2CH2CH2 NH2, -CH2CH2CH2CH2NH2, -CH2CH(NH2)CH3, -CH2CH(NH2)CH2CH3, -CH(NH2)CH2CH3 and -C(CH3)2 (CH2NH2), -CH2CH2CH2CH2CH2NH2, and -CH2CH2CH(NH2)CH2CH3. An amino(alkyl) group can be unsubstituted or substituted with one or two of the following groups C1-C6alkoxy, C6-C14aryl, C1-C9heteroaryl, C3-C8cycloalkyl, and C1-C6alkyl which may be the same or different. "Aryl" refers to an aromatic hydrocarbon group. If not otherwise specified, in this specification the term aryl refers to a C6-C14aryl group. Examples of an C6-C14aryl group include, but are not limited to, phenyl, 1-naphthyl, 2-naphthyl, 3-biphen-l-yl, anthryl, tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl, and acenaphthenyl, groups. An aryl group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: C1-C6alkyl, C3-C8cycloalkyl, C1-C6perfluoroalkyl-, halo, haloalkyl- , hydroxyl, C1-C6hydroxylalkyl-, -NH2, aminoalkyl-, dialkylamino-, -COOH, -C(O)O-(C1-C6alkyl), -OC(O)(C1-C6alkyl), N-alkylamido-, -C(O)NH2, (C1-C6alkyl)amido-, or -NO2. "(Aryl)alkyl" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with an C6-C14aryl group as defined above. (C6-C14Aryl)alkyl moieties include benzyl, 1-phenylethyl, 2-phenylethyl, 3-phenylpropyl, 2-phenylpropyl, 1-naphthylmethyl, 2-naphthylmethyl and the like. An (aryl)alkyl group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, hydroxyl, -NH(C1-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)O(Cl1-C6alkyl), -C(O)(C1-C6alkyl), C6-C14aryl, C1-C9heteroaryl, C3-C8cycloalkyl, haloalkyl-, aminoalkyl-, -OC(O)(C1-C6alkyl), C1-C6carboxyamidoalkyl-, or -NO2. "(Aryl)amino" refers to a radical of formula aryl-NH-, wherein "aryl" is as defined above. Examples of (C6-C14aryl)amino radicals include, but are not limited to, phenylamino (anilido), 1-naphthylamino, 2-naphthylamino and the like. An (aryl)amino group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)O(Cl1-C6alkyl), -C(O)(C1-C6alkyl), C6-C14aryl, C1-C9heteroaryl, or C3-C8cycloalkyl. "(Aryl)oxy" refers to the group Ar-O- where Ar is an aryl group, as defined above. Exemplary (C6-C14aryl)oxy groups include but are not limited to phenyloxy, a-naphthyloxy, and P-naphthyloxy. A (aryl)oxy group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: C1-C6alkyl, halo, haloalkyl-, hydroxyl, C1-C6hydroxylalkyl-, -NH2, aminoalkyl-, -dialkylamino-, -COOH, -C(O)O-(C1-C6alkyl), -OC(O)(C1-C6alkyl), N-alkylamido-, -C(O)NH2, (C1-C6alkyl)amido-, or -NO2. "Cycloalkyl" refers to a monocyclic, saturated hydrocarbon ring containing 3-8 carbon atoms. Representative examples of a C3-C8cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. A cycloalkyl can be unsubstituted or independently substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-C6alkyl), -N(d-C6alkyl)(d-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)O(C1-C6alkyl), -C(O)(C1-C6alkyl), C6-C14aryl, C1-C9heteroaryl, or C3-C8cycloalkyl, haloalkyl-, aminoalkyl-, -OC(O)(C1-C6alkyl), C1-C6carboxyamidoalkyl-, or -NO2. Additionally, each of any two hydrogen atoms on the same carbon atom of the cycloalkyl ring can be replaced by an oxygen atom to form an oxo (=O) substituent or the two hydrogen atoms can be replaced by an alkylenedioxy group so that the alkylenedioxy group, when taken together with the carbon atom to which it is attached, form a 5- to 7-membered heterocycle containing two oxygen atoms. "Bicyclic cycloalkyl" refers to a bicyclic, saturated hydrocarbon ring system containing 6-10 carbon atoms. Representative examples of a C6-C10bicyclic cycloalkyl include, but are not limited to, cis-1-decalinyl, trans 2-decalinyl, cis-4-perhydroindanyl, and trans-7-perhydroindanyl. A bicyclic cycloalkyl can be unsubstituted or independently substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)O(C1-C6alkyl), -C(O)(C1-C6alkyl), C6-C14aryl, d-dheteroaryl, or C3-C8cycloalkyl, haloalkyl-, aminoalkyl-, -OC(O)(C1-C6alkyl), C1-C6carboxyamidoalkyl-, or -NO2. Additionally, each of any two hydrogen atoms on the same carbon atom of the bicyclic cycloalkyl rings can be replaced by an oxygen atom to form an oxo (=O) substituent or the two hydrogen atoms can be replaced by an alkylenedioxy group so that the alkylenedioxy group, when taken together with the carbon atom to which it is attached, form a 5- to 7-membered heterocycle containing two oxygen atoms. "Carboxyamidoalkyl-" refers to a primary carboxyamide (-CONH2), a secondary carboxyamide (CONHR') or a tertiary carboxyamide (CONR'R"), where R' and R" are the same or different substituent groups selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C6-C14aryl, C1-C9heteroaryl, or C3-C8cycloalkyl, attached to the parent compound by an alkylene group as defined above. Exemplary C1-C6carboxyamidoalkyl- groups include but are not limited to NH2C(O)-CH2-, CH3NHC(O)-CH2CH2-, (CH3)2NC(O)-CH2CH2CH2-, CH2=CHCH2NHC(O)- CH2CH2CH2CH2-, HCCCH2NHC(O)-CH2CH2CH2CH2CH2-, C6H5NHC(O)- CH2CH2CH2CH2CH2CH2-. S-pyridylNHCCOVCCHfCHCCHz-. and cyclopropyl-CH2NHC(O)-CH2CH2C(CH3)2CH2-. "Cycloalkenyl" refers to non-aromatic, carbocyclic rings containing 3-10 carbon atoms with one or more carbon-to-carbon double bonds within the ring system. The "cycloalkenyl" may be a single ring or may be multi-ring. Multi-ring structures may be brifd or fused ring structures. A cycloalkenyl can be unsubstituted or independently substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)O(C1-C6alkyl), -C(O)(C1-C6alkyl), C6-C14aryl, C1-C9heteroaryl, or C3-C8cycloalkyl, haloalkyl-, aminoalkyl-, -OC(O)(C1-C6alkyl), C1-C6carboxyamidoalkyl-, or -NO2 Additionally, each of any two hydrogen atoms on the same carbon atom of the cycloalkenyl rings may be replaced by an oxygen atom to form an oxo (=0) substituent or the two hydrogen atoms may be replaced by an alkylenedioxy group so that the alkylenedioxy group, when taken together with the carbon atom to which it is attached, form a 5-to 7-membered heterocycle containing two oxygen atoms. Examples of C3-C10cycloalkenyls include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, 4,4a-octalin-3-yl, and cyclooctenyl. "Di(alkyl)amino-" refers to a nitrogen atom which has attached to it two alkyl groups, as defined above. Each alkyl group can be independently selected from the alkyl groups. Representative examples of an di(C1-C6alkyl)amino- group include, but are not limited to, -N(CH3)2, -N(CH2CH3)(CH3), -N(CH2CH3)2, -N(CH2CH2CH3)2, -N(CH2CH2CH2CH3)2, -N(CH(CH3)2)2, -N(CH(CH3)2)(CH3), -N(CH2CH(CH3)2)2, -NH(CH(CH3)CH2CH3)2, -N(C(CH3)3)2, -N(C(CH3)3)(CH3), and -N(CH3)(CH2CH3). The two alkyl groups on the nitrogen atom, when taken together with the nitrogen to which they are attached, can form a 3- to 7-membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle can be replaced with -N(R)-, -O-, or -S(O)r-. R is hydrogen, C1-C6alkyl, C3-C8cycloalkyl, C6-C14aryl, C1-C9heteroaryl, amino(C1-C6alkyl), or arylamino. Variable r is 0, 1, or 2. "Halo" or "Halogen" is -F, -Cl, -Br or -I. "Haloalkyl" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with -F, -Cl -Br, or -L Each substitution can be independently selected from -F, -Cl, -Br, or -I. Representative examples of an C1-C6haloalkyl group include, but are not limited to -CH2F, -CC13, -CF3, CH2CF3, -CH2C1, -CH2CH2Br, -CH2CH2I, -CH2CH2CH2F, -CH2CH2CH2Cl, -CH2CH2CH2CH2Br, -CH2CH2CH2CH2I, -CH2CH2CH2CH2CH2Br, -CH2CH2CH2CH2CH2I, -CH2CH(Br)CH3, -CH2 CH(Cl)CH2CH3, -CH(F)CH2CH3 and -C(CH3)2 (CH2Cl). "Heteroaryl" refers to 5-10-membered mono and bicyclic aromatic groups containing at least one heteroatom selected from oxygen, sulfur and nitrogen e.g. it can suitably contain 1 to 3 heteroatoms. Examples of monocyclic C1-C5heteroaryl radicals include, but are not limited to, pyrrolyl, thiazinyl, diazinyl, triazinyl, tetrazinyl, imidazolyl, tetrazolyl, isoxazolyl, furanyl, furazanyl, oxazolyl, thiazolyl, isothiazolyl, thiophenyl, pyrazolyl, triazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, N-pyridyl, 2-pyridyl, 3-pyridyl and 4-pyridyl. Examples of C1-Cgbicyclic heteroaryl radicals include but are not limited to, benzimidazolyl, indolyl, isoquinolinyl, quinolinyl, quinazolinyl, purinyl, benzisoxazolyl, benzoxazolyl, benzthiazolyl, benzodiazolyl, benzotriazolyl, isoindolyl and indazolyl. A heteroaryl group can be unsubstituted or substituted with one or more of the following groups: C1-C6alkyl, halo, haloalkyl-, hydroxyl, C1-C6hydroxylalkyl-, -NH2, aminoalkyl-, dialkylamino-, -COOH, -C(O)O-(C1-C6alkyl), -OC(O)(C1-C6alkyl), N-alkylamido-, -C(O)NH2, (C1-C6alkyl)amido-, or -NO2. "Heteroaryl(alkyl)" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a heteroaryl group as defined above. Heteroaryl(C1-C6alkyl) moieties include 2-pyridylmethyl, 2-thiophenylethyl, 3-pyridylpropyl, 2-quinolinylmethyl, 2-indolylmethyl, and the like. A heteroaryl(alkyl) group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)O(C1-C6alkyl), -C(O)(C1-C6alkyl), monocyclic C1-C6heterocycle, C6-C14aryl, C1-C9heteroaryl, or C3-C8cycloalkyl. "(Heteroaryl)oxy" refers to the group Het-O- where Het is a heteroaryl group, as defined above. Exemplary (C1-C9heteroaryl)oxy groups include but are not limited to pyridin-2-yloxy, pyridin-3-yloxy. pyrimidin-4-yloxy, and oxazoI-5-yloxy. A (heteroaryl)oxy group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: C1-C6alkyl, halo, haloalkyl-, hydroxyl, C1-C6hydroxylalkyl-, -NH2, aminoalkyl-, dialkylamino-, -COOH, -C(O)O-(C1-C6alkyl), -OC(O)(C1-C6alkyl), N-alkylamido-, -C(O)NH2, (C1-C6alkyl)amido-, or -NO2. The term "heteroatom" refers to a sulfur, nitrogen, or oxygen atom. "Heterocycle" refers to 3-10-membered mono and bicyclic groups containing at least one heteroatom selected from oxygen, sulfur and nitrogen e.g. it can suitably contain 1 to 3 heteroatoms. A heterocycle may be saturated or partially saturated. Exemplary C1-C9heterocycle groups include but are not limited to aziridine, oxirane, thiirane, pyrroline, pyrrolidine, dihydrofuran, tetrahydrofuran, dihydrothiophene, tetrahydrothiophene, dithiolane, piperidine, tetrahydropyran, pyran, thiane, thiine, piperazine, oxazine, thiazine, dithiane, dioxane, tetrahydroquinoline, and tetrahydroisoquinoline. "Heterocyclyl(alkyl)" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a heterocycle group as defined above. Heterocyclyl(C1-C6alkyl) moieties include 1-piperazinylethyl, 4-morpholinylpropyl, 6-piperazinylhexyl, and the like. A heterocyclyl(alkyl) group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: halogen, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C,-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, -C(O)OH, -C(O)O(C1-C6alkyl), -C(O)(C1-C6alkyl), monocyclic C1-C6heterocycle, C6-C14aryl, C1-C9heteroaryl, or C3-C8cycloalkyl. "Hydroxylalkyl-" refers to an alkyl group, as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with hydroxyl groups. Examples of C1-C6hydroxylalkyl- moieties include, for example, -CH2OH, -CH2CH2OH, -CH2CH2CH2OH, -CH2CH(OH)CH2OH, -CH2CH(OH)CH3, -CH(CH3)CH2OH and higher homologs. "Hydroxylalkenyl-" refers to a straight or branched chain hydrocarbon, containing 3-6 carbon atoms, and at least one double bond, substituted on one or more sp3 carbon atom with a hydroxyl group. Examples of C3-C6hydroxylalkenyl- moieties include chemical groups such as -CH=CHCH2OH, -CH(CH=CH2)OH, -CH2CH=CHCH2OH, -CH(CH2CH=CH2)OH, - CH=CHCH2CH20H. -CH(CH=CHCH3)OH. -CH=CHCH(CH3)0H, -CH2CH(CH=CH2)OH, and higher homologs. "Monocyclic heterocycle" refers to a monocyclic cycioalkyl, or cycloalkenyl in which 1-4 of the ring carbon atoms have been independently replaced with an N, O or S atom. The monocyclic heterocyclic ring can be attached via a nitrogen, sulfur, or carbon atom. Representative examples of a monocyclic C1-Ceheterocycle group include, but are not limited to, piperidinyl, 1,2,5,6-tetrahydropyridinyl, piperazinyl, morpholinyl, oxazinyl, thiazinyl, pyrrolinyl, pyrrolidinyl, and homopiperidinyl. A monocyclic heterocycle group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: C1-Cgacyl, C1-C6alkyl, heterocyclyl(C1-C6alkyl), (C6-C]4aryl)alkyl, halo, Cr Cehaloalkyl-, hydroxyl, C1-Cghydroxylalkyl-, -NH2, aminoalkyl-, -dialkylamino-, -COOH, -C(O)0-(C1-C6alkyl), -OC(O)(C1-C6alkyl), (C6-C14aryl)alkyl-O-C(O)-, N-alkylamido-, -C(O)NH2, (C1-C6alkyl)amido-, or -N02. "Bicyclic heterocycle" refers to a bicyclic cycioalkyl or bicyclic cycloalkenyl in which 1-4 of the ring carbon atoms have been independently replaced with an N, O or S atom. The bicyclic heterocyclic ring can be attached via a nitrogen, sulfur, or carbon atom. Representative examples of a bicyclic C1-Cgheterocycle group include, but are not limited to, indolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, and chromanyl. A bicyclic heterocycle group can be unsubstituted or substituted with one or more e.g. 1 to 3 of the following groups which may be the same or different: CpCgacyl, C1-C6alkyl, heterocyclyl(CrC6alkyl), (C6-Ci4aryl)alkyl, halo, C1-Cghaloalkyl-, hydroxyl, C1-C6hydroxylalkyl-, -NH2, aminoalkyl-, -dialkylamino-, -COOH, -C(O)0-(C1-C6alkyl), -OC(O)(CrC6alkyl), (C6-Ci4aryl)alkyl-O-C(O)-, N-alkylamido-, -C(O)NH2, (d-Csalkyamido-, or -N02. "Perfluoroalkyl-" refers to a straight or branched chain hydrocarbon having two or more fluorine atoms. Examples of a CrC6perfluoroalkyl- group include CF3, CH2CF3, CF2CF3 and CH(CF3)2. The term "optionally substituted", unless otherwise specified, as used herein means that at least one hydrogen atom e.g. 1 to 3 atoms of the optionally substituted group has been substituted with halogen, -NH2, -NH(C1-C6alkyl), -N(C1-C6alkyl)(C1-C6alkyl), -N(C1-C3alkyl)C(O)(C1-C6alkyl), -NHC(O)(C1-C6alkyl), -NHC(O)H, -C(O)NH2, -C(O)NH(C1-C6alkyl), -C(O)N(C1-C6alkyl)(C1-C6alkyl), -CN, hydroxyl, -O(C1-C6alkyl), C1-C6alkyl, - C(O)OH, -C(O)O(Cl1,-C6alkyl). -C(O)(C1-C6alkyl. C6-C14aryl, C1-C9heteroaryl, or C3-C8cycloalkyl. A "subject" is a mammal, e.g., a human, moose, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or gorilla. The 3H-[l,2,3]triazolo[4,5-d]pyrimidine compounds of the present invention exhibit an PI3K inhibitory activity and therefore, can be utilized in order to inhibit abnormal cell growth in which PI3K plays a role. Thus, the 3H-[l,2,3]triazolo[4,5-d]pyrimidine compounds are effective in the treatment of disorders with which abnormal cell growth actions of PI3K are associated, such as restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, cancer, etc. In particular, the 3H-[l,2,3]triazolo[4,5-djpyrimidine compounds of the present invention possess excellent cancer cell growth inhibiting effects and are effective in treating cancers, preferably all types of solid cancers and malignant lymphomas, and especially, leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain tumor, advanced renal cell carcinoma, acute lymphoblastic leukemia, malignant melanoma, soft-tissue or bone sarcoma, etc. The 3H-[l,2,3]triazolo[4,5-d]pyrimidine compounds of the present invention exhibit an mTOR inhibitory activity and therefore, can be utilized in order to inhibit abnormal cell growth in which mTOR plays a role. Thus, the 3H-[l,2,3]triazolo[4,5-d]pyrimidine compounds are effective in the treatment of disorders with which abnormal cell growth actions of mTOR are associated, such as restenosis, atherosclerosis, bone disorders, arthritis, diabetic retinopathy, psoriasis, benign prostatic hypertrophy, atherosclerosis, inflammation, angiogenesis, immunological disorders, pancreatitis, kidney disease, cancer, etc. In particular, the 3H-[l,2,3]triazolo[4,5-d]pyrimidine compounds of the present invention possess excellent cancer cell growth inhibiting effects and are effective in treating cancers, preferably all types of solid cancers and malignant lymphomas, and especially, leukemia, skin cancer, bladder cancer, breast cancer, uterus cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, brain tumor, advanced renal cell carcinoma, acute lymphoblastic leukemia, malignant melanoma, soft-tissue or bone sarcoma, etc. When administered to an animal, the compounds of the present invention or pharmaceutically acceptable salts thereof can be administered neat or as a component of a composition that comprises a pharmaceutically acceptable carrier or vehicle. A composition of the invention can be prepared using a method comprising admixing the compound of the present invention or pharmaceuticaUy acceptable salt thereof and a physiologically acceptable carrier, excipient, or diluent. Admixing can be accomplished using methods well known in the art. The present compositions, comprising compounds of the present invention or pharmaceuticaUy acceptable salts thereof can be administered orally, or by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral, rectal, vaginal, and intestinal mucosa, etc.) and can be administered together with another therapeutic agent. Administration can be systemic or local. Various known delivery systems, including encapsulation in liposomes, microparticles, microcapsules, and capsules, can be used. Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intracerebral, intravaginal, transdermal, rectal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin. In some instances, administration will result of release of the compound of the present invention or pharmaceuticaUy acceptable salt thereof into the bloodstream. The mode of administration is left to the discretion of the practitioner. In one aspect, the compound of the present invention or pharmaceuticaUy acceptable salt thereof is administered orally. In another aspect, the compound of the present invention or pharmaceuticaUy acceptable salt thereof is administered intravenously. In another aspect, it can be desirable to administer the compound of the present invention or pharmaceuticaUy acceptable salt thereof locally. This can be achieved, for example, by local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository or edema, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In certain aspects, it can be desirable to introduce the compound of the present invention or pharmaceuticaUy acceptable salt thereof into the central nervous system, circulatory system or gastrointestinal tract by any suitable route, including intraventricular, intrathecal injection, paraspinal injection, epidural injection, enema, and by injection adjacent to the peripheral nerve. An intraventricular catheter, for example, can facilitate intraventricular injection attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain aspects, the compound of the present invention or pharmaceutically acceptable salt thereof can be formulated as a suppository, with traditional binders and excipients such as triglycerides. In another aspect, compound of the present invention or pharmaceutically acceptable salt thereof can be delivered in a vesicle, in particular a liposome by methods known in the art. In yet another aspect, the compound of the present invention or pharmaceutically acceptable salt thereof can be delivered in a controlled-release system or sustained-release system by methods known in the art. In one aspect, a pump can be used. In another aspect, polymeric materials can be used. In yet another aspect, a controlled- or sustained-release system can be placed in proximity of a target of the compound of the present invention or a pharmaceutically acceptable salt thereof, e.g., the reproductive organs, thus requiring only a fraction of the systemic dose. The present compositions can optionally comprise a suitable amount of a pharmaceutically acceptable excipient. Such pharmaceutically acceptable excipients can be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The excipients can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea and the like. In addition, auxiliary, stabilizing, thickening, lubricating, and coloring agents can be used. In one aspect, the excipients are sterile when administered to an animal. The excipient should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms. Water is a particularly useful excipient in the practice of this invention where administration is performed intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid excipients, particularly for injectable solutions. Suitable excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents known in the art. Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups, and elixirs. The compound of the present invention or pharmaceutically acceptable salt thereof can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both, or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives including solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particular containing additives as above, e.g., cellulose derivatives, including sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils {e.g., fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant. The present compositions can take the form of solutions, suspensions, emulsion, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form suitable for use. In one aspect, the composition is in the form of a capsule. In one aspect, the compound of the present invention or pharmaceutically acceptable salt thereof is formulated in accordance with known procedures as a composition adapted for oral administration to humans. Compositions for oral delivery can be in the form of tablets, lozenges, buccal forms, troches, aqueous or oily suspensions or solutions, granules, powders, emulsions, capsules, syrups, or elixirs for example. Orally administered compositions can contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. In powders, the carrier can be a finely divided solid, which is an admixture with the finely divided compound of the present invention 3r pharmaceutically acceptable salt thereof. In tablets, the compound of the present invention or pharmaceutically acceptable salt thereof is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets can contain up to about 99% of the compound of the present invention or pharmaceutically acceptable salt thereof. Capsules may contain mixtures of the compounds of the present invention or pharmaceutically acceptable salts thereof with inert fillers and/or diluents such as pharmaceutically acceptable starches (e.g., corn, potato, or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (such as crystalline and microcrystalline celluloses), flours, gelatins, gums, etc. Tablet formulations can be made by conventional compression, wet granulation, or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents (including, but not limited to, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvinylpyrroldine, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting waxes, and ion exchange resins. Surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine. Moreover, when in a tablet or pill form, the compositions can be coated to delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained action over an extended period of time. Selectively permeable membranes surrounding an osmotically active driving compound or a pharmaceutically acceptable salt of the compound are also suitable for orally administered compositions. In these latter platforms, fluid from the environment surrounding the capsule can be imbibed by the driving compound, which swells to displace the agent or agent composition through an aperture. These delivery platforms can provide an essentially zero order delivery profile as opposed to the spiked profiles of immediate release formulations. A time-delay material such as glycerol monostearate or glycerol stearate can also be used. Oral compositions can include standard excipients such as mannitol, lactose, siarch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one aspect, the excipients are of pharmaceutical grade. In another aspect, the compound of the present invention or pharmaceutically acceptable salt thereof can be formulated for intravenous administration. Typically, compositions for intravenous administration comprise sterile isotonic aqueous buffer. Where necessary, the compositions can also include a solubilizing agent. Compositions for intravenous administration can optionally include a local anesthetic such as lignocaine to lessen pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the compound of the present invention or pharmaceutically acceptable salt thereof is to be administered by infusion, it can be dispensed, for example, with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the compound of the present invention or pharmaceutically acceptable salt thereof is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients can be mixed prior to administration. In another aspect, the compound of the present invention or pharmaceutically acceptable salt thereof can be administered transdermally through the use of a transdermal patch. Transdermal administrations include administrations across the surface of the body and the inner linings of the bodily passages including epithelial and mucosal tissues. Such administrations can be carried out using the present compounds of the present invention or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (e.g., rectal or vaginal). Transdermal administration can be accomplished through the use of a transdermal patch containing the compound of the present invention or pharmaceutically acceptable salt thereof and a carrier that is inert to the compound of the present invention or pharmaceutically acceptable salt thereof, is non-toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of forms such as creams or ointments, pastes, gels, or occlusive devices. The creams or ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the compound of the present invention or pharmaceutically acceptable salt thereof into the blood stream, such as a semi-permeable membrane covering a reservoir containing the compound of the present invention or pharmaceutically acceptable salt thereof with or without a carrier, or a matrix containing the active ingredient. The compounds of the present invention or pharmaceutically acceptable salts thereof may be administered rectally or vaginally in the form of a conventional suppository. Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water-soluble suppository bases, such as polyethylene glycols of various molecular weights, may also be used. The compound of the present invention or pharmaceutically acceptable salt thereof can be administered by controlled-release or sustained-release means or by delivery devices that are known to those of ordinary skill in the art. Such dosage forms can be used to provide controlled-or sustained-release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled- or sustained-release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. The invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are adapted for controlled- or sustained-release. Advantages of controlled- or sustained-release compositions include extended activity of the drug, reduced dosage frequency, and increased compliance by the animal being treated. In addition, controlled-or sustained-release compositions can favorably affect the time of onset of action or other characteristics, such as blood levels of the compound of the present invention or a pharmaceutically acceptable salt thereof, and can thus reduce the occurrence of adverse side effects. Controlled- or sustained-release compositions can initially release an amount of the compound of the present invention or pharmaceutically acceptable salt thereof that promptly produces the desired therapeutic or prophylactic effect, and gradually and continually release other amounts of the compound of the present invention or pharmaceutically acceptable salt thereof to maintain this level of therapeutic or prophylactic effect over an extended period of time. In certain aspects, the present invention is directed to prodrugs of the compounds of the present invention or pharmaceutically acceptable salts of compounds of the present invention of the present invention. Various forms of prodrugs are known in the art. The amount of the compound of the present invention or pharmaceutically acceptable salt thereof that is effective for inhibiting mTOR or PI3K in a subject.. In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed can also depend on the route of administration, the condition, the seriousness of the condition being treated, as well as various physical factors related to the individual being treated, and can be decided according to the judgment of a health-care practitioner. Equivalent dosages may be administered over various time periods including, but not limited to, about every 2 hours, about every 6 hours, about every 8 hours, about every 12 hours, about every 24 hours, about every 36 hours, about every 48 hours, about every 72 hours, about every week, about every two weeks, about every three weeks, about every month, and about every two months. The number and frequency of dosages corresponding to a completed course of therapy will be determined according to the judgment of a health-care practitioner. The amount of the compound of the present invention or pharmaceutically acceptable salt thereof that is effective for treating or preventing an mTOR-related disorder or for treating or preventing a PI3K-related disorder will typically range from about 0.001 mg/kg to about 250 mg/kg of body weight per day, in one aspect, from about 1 mg/kg to about 250 mg/kg body weight per day, in another aspect, from about 1 mg/kg to about 50 mg/kg body weight per day, and in another aspect, from about 1 mg/kg to about 20 mg/kg of body weight per day. In one aspect, the pharmaceutical composition is in unit dosage form, e.g., as a tablet, capsule, powder, solution, suspension, emulsion, granule, or suppository. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage form can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. Such unit dosage form may contain from about 1 mg/kg to about 250 mg/kg, and may be given in a single dose or in two or more divided doses. The present methods for treating or preventing an mTOR-related disorder, can further comprise administering another therapeutic agent to the animal being administered the compound of the present invention or pharmaceutically acceptable salt thereof. In one aspect, the other therapeutic agent is administered in an effective amount. Effective amounts of other therapeutic agents to be administered simultaneously or sequentially with the present compound or pharmaceutically acceptable salt thereof are well known to those skilled in the art. However, it is well within the skilled artisan's purview to determine the other therapeutic agent's optimal effective amount range. Suitable other therapeutic agents useful in the methods and compositions of the present invention include, but are not limited to temozolomide, a topoisomerase I inhibitor, procarbazine, dacarbazine, gemcitabine, capecitabine, methotrexate, taxol, taxotere, mercaptopurine, thioguanine, hydroxyurea, cytarabine, cyclophosphamide, ifosfamide, nitrosoureas, cisplatin, carboplatin, mitomycin, dacarbazine, procarbizine, etoposide, teniposide, campathecins, bleomycin, doxorubicin, idarubicin, daunorubicin, dactinomycin, plicamycin, hydroxyzine, glatiramer acetate, interferon beta-la, interferon beta-lb, mitoxantrone, natalizumab, L-asparaginase, doxorubicin, epirubicin, 5-fluorouracil, taxanes such as docetaxel and paclitaxel, leucovorin, levamisole, irinotecan, estramustine, etoposide, nitrogen mustards, BCNU, nitrosoureas such as carmustine and lomustine, vinca alkaloids such as vinblastine, vincristine and vinorelbine, platinum complexes such as cisplatin, carboplatin and oxaliplatin, imatinib mesylate, hexamethylmelamine, topotecan, tyrosine kinase inhibitors, tyrphostins herbimycin A, genistein, erbstatin, and lavendustin A. In one aspect, the compound of the present invention or pharmaceutically acceptable salt thereof is administered concurrently with another therapeutic agent. In one aspect, a composition comprising an effective amount of the compound of the present invention or pharmaceutically acceptable salt thereof and an effective amount of another therapeutic agent within the same composition can be administered. In another aspect, a composition comprising an effective amount of the compound of the present invention or a pharmaceutically acceptable salt of the compound of the present invention and a separate composition comprising an effective amount of another therapeutic agent can be concurrently administered. In another aspect, an effective amount of the compound of the present invention or a pharmaceutically acceptable salt thereof of the present invention administered prior to or subsequent to administration of an effective amount of another therapeutic agent. In another aspect, a method of treating advanced renal cell carcinoma, comprising administering to a mammal in need thereof the compounds or a pharmaceutically acceptable salt thereof of the present formula 1 in an amount effective to treat advanced renal cell carcinoma. In another aspect, a method of treating acute lymphoblastic leukemia, comprising administering to a mammal in need thereof the compounds or a pharmaceutically acceptable salt thereof of any of the present formula 1 in an amount effective to treat acute lymphoblastic leukemia. In another aspect, a method of treating acute lymphoblastic leukemia, comprising administering to a mammal in need thereof the compounds or a pharmaceutically acceptable salt thereof of any of the present formula 1 in an amount effective to treat malignant melanoma. In another aspect, a method of treating acute lymphoblastic leukemia, comprising administering to a mammal in need thereof the compounds or a pharmaceutically acceptable salt thereof of any of the present formula 1 in an amount effective to treat soft-tissue or bone sarcoma. The general procedures used to synthesize the compounds of Formula 1 are described in Schemes 1-10 and are illustrated in the examples. Reasonable variations of the described procedures, which would be evident to one skilled in the art, are intended to be within the scope of the present invention: (Formula Removed) The key intermediate 3-(l-BOC-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H- [l,2,3]triazoIo[4,5-d]pyrimidine was made in four steps from the readily available 2,4,6-trichloropyrimidine. This BOC protected key intermediate could be coupled with a variety of runctionalized boronic acids. Removal of the BOC protecting group, followed by reductive amination gave an array of piperidine compounds, elaborated on the 1-N atom. (Formula Removed) 3-(5-Chloro-7-morpholin-4-yl-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl)-azetidine-l-carboxylicacid tert-butyl ester was also made by a four-step process. The protected aziridine readily couples with 4-aminophenylboronic acid. Elaboration to a wide variety of urea compounds is done by phosgene mediated coupling with aromatic amines. (Formula Removed) (a) 4-Aminophenylboronic acid/ (PPh3)4Pd (O)/ DME/ NaHCO3/ µ wave/ 150 °C (b)COCl2/ Et3N/ R'NH2 Simple 5-chloro-3-alkyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine intermediate compounds were prepared using a four-step procedure. Suzuki coupling of these chlorinated intermediates with 4-aminophenylboronic acid gave an aniline intermediate. Elaboration to a wide variety of urea compounds is done by phosgene mediated coupling with aromatic amines. (Formula Removed) 3-(l-Benzyl-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine smoothly underwent Suzuki coupling with a variety of aryl and heteroaryl boronic acids. Elaboration to a wide variety of urea compounds is done by phosgene mediated coupling with alkyl amines. (Formula Removed) (a) 3-Hydroxyphenylboronic acid/ (Ph3)4Pd/ NaHCO3/ Dimethoxyethane/ µwave or Thermal R = (Formula Removed) 2,6-Dichloro-5-nitro-4-morpholino-pyrimidine, prepared as shown in Scheme 1, reacted with a wide variety of primary amines. Triazole formation, followed by Suzuki coupling with m-hydroxyphenylboronic acid gave the phenols shown above. (Formula Removed) (a) 3-Hydroxyphenylboronic acid/ (PPh3)4Pd (O)/ DME/ NaHC03/ \i wave/150 °C (b) TFA/ CH2Cl2 / room temperature (c)R1R2NH/DCDI/THF 2,6-Dichloro-5-nitro-4-morpholino-pyrimidine, prepared as shown in Scheme 1, was converted to tert-butyl 2-(5-(3-hydroxyphenyl)-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl)acetate. Suzuki coupling with m-hydroxypheneylboronic acid gave the tert-butyl ester shown. Removal of the ester group gave an acetic acid, which was converted to a variety of amides. (Formula Removed) (a) 3-Hydroxyphenylboronic acid/ (PPh3)4Pd (0)/ DME/ NaHC03/ µ wave/150 °C (b) NaOH/ THF/ MeOH/ RT (c) R1R2NH/ DCDI/THF 2,6-Dichloro-5-nitro-4-morpholino-pyrimidine, prepared as shown in Scheme 1, was converted to methyl 4-((5-chloro-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl)methyl)benzoate. Suzuki coupling with m-hydroxypheneylboronic acid gave the methyl ester shown. Removal of the ester group gave a benzoic acid, which was converted to a variety of amides. (Formula Removed) (a) 3-Hydroxyphenylboronic acid/ (PPh3)4Pd (O)/ DME/ NaHCO3/ µ wave/ 150 °C (b) NaOH/ THF/ MeOH/ room temperature (c) R1R2NH/ DCDI/ THF 2,6-Dichloro-5-nitro-4-morpholino-pyrimidine, prepared as shown in Scheme 1, was converted to methyl 3-((5-chloro-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl)methyl)benzoate. Suzuki coupling with m-hydroxypheneylboronic acid gave the methyl ester shown. Removal of the ester group gave a benzoic acid, which was converted to a variety of amides. (Formula Removed) As an alternative synthesis, the triazole ring could be constructed first and the pyrimidine ring annealed to it. 5-Amino-l-substituted-lH-l,2,3-triazole-4-carboxamide compounds could be made from substituted azide compounds and 2-cyanoacetamide. Reaction with urea would give the 3-substituted-3H-[l,2,3]triazolo[4,5-d]pyrimidine-5,7(4H,6H)-dione shown. Treatment with POCl3 would give the key intermediate 5,7-dichloro-3-substituted-3H-[l,2,3]triazolo[4,5-d]pyrimidine. Reaction with an amine 4 and Suzuki coupling with a boronic acid of the formula (R2)r-Ar-B(OH)2 would give a variety of final products of formula 1. (Formula Removed) A general synthesis of 1 starts with the readily available 2,4,6-halo-5-nitropyrimidine compounds 3. Reaction with amine 4 followed by annulation of the triazole ring gave the 3H-[l,2,3]triazolo[4,5-d]pyrimidine 2. Suzuki coupling with a boronic acid of the formula (R2)r-Ar-B(OH)2 gave a variety of final products of formula 1. EXAMPLES The following procedures were used to synthesize the 3H-[l,2.3]triazolo[4,5-d]pyrimidine compounds in the Examples that follow. EXPERIMENTAL PROCEDURES Preparation of 2,6-dichloro-5-nitro-4-morpholino-pyrimidine. To a solution of 2,4,6-trichloronitropyrimidine (6.20 g, 27.2 mmol) in CH2Cl2 (170 mL) at 0 °C was added a solution of morpholine (2.34 g, 27.2 mmol) and NEt3 (2.74 g, 27.2 mmol) in CH2CI2 (70 mL) over a period of 1hr. The reaction mixture was stirred for another 1 hr at 0 °C and allowed to warm to 20 °C and stirred for 12 hours to drive the reaction to competition. For purification, silica gel (20 g) was added to the reaction mixture and the solvent was removed so that product was adsorbed on the silica gel. The material was purified by flash chromatography using CH2Cl2 eluent the product was obtained as yellow solid after concentration. Yield: 6.90 g, 91%. MS (ESI) m/z 279. Procedure 1 Step1 Synthesis of 2-chIoro-6-alkylamino-5-nitro-4-morpholino-pyrimidines with primary amines. To an appropriately substituted CH2Cl2 solution of the primary amine (leq) in CH2Cl2 (170 mL) at 0 °C was added a solution of 2,6-dichloro-5-nitro-4-morpholino-pyrimidine (2.34 g, 27.2 mmol) and NEt3 (2.74 g, 27.2 mmol) dissolved in CH2CI2 (70 mL) over a period of 1hr. The reaction mixture was stirred for another 1 hr at 0 °C and allowed to warm to 20 °C and stirred for 1-4 hours to drive the reaction to completion. The product was purified by SiO2 column chromatography by eluting it with CH2Cl2. Yellow solid (73-91% yield). Step 2 Reduction of 2-chIoro-6-alkylamino-5-nitro-4-morphoIino-pyrimidine. In a three-necked flask was suspended under nitrogen atmosphere (2-chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-yl)-alkyl-amines (1.0 mmol) and Raney™ nickel (850 mg) in methanol (30 mL). To the stirring reaction mixture was added slowly hydrazine (0.3 mL, 9 mmol, 9 eq) and the stirring was continued for 0.5 hours to drive the reduction to completion. The reaction mixture was filtered over Celite™ and the filtrate was evaporated and purified by flash purified by chromatography using CH2Cl2/MeOH/NH3(l0:1:0.1) to obtain the product (73-100% yield) as off-white solid. Step 3 Synthesis of 8-aza-9-aIkyl-2-chIoro-6-morphoIino-purines. To a stirred solution of N4-alkyl-2-chloro- 6-morpholin-4-yl-pyrimidine-4,5-diamine (1 mmol) in acetic acid/water (1:1, 4 mL) at 0 °C was added aqueous (0.5 N) NaN02-solution (4 mL, 2 mmol, 2 eq) and the reaction mixture was allowed to stir for 2 hours. The off-white solid was collected by filtration and dried in vacuum to give the 8-aza-9-alkyl-2-chloro-6-morpholino-purines (64-95% yield). Procedure 2 Preparation of 8-aza-9-alkyl-2-(aryl/heteroaryl)-6-morpholino-purines._To a microwave processing tube was added dimethoxyethane (1.6 mL), aqueous Na2CO3 (2 M solution, 0.4 mL, 0.8 mmol, 2 eq), (Ph3P)4Pd (46 mg, 0.08 mmol), and the appropriately substituted boronic acid or ester (0.75 mmol, 2 eq) and the 8-aza-9-alkyl-2-chloro-6-morpholino-purines (0.38 mmol) and the vessel was sealed. The mixture was heated to 140 °C for 45 minutes. The solvents were removed on a rotary evaporator and the crude compound was purified by silica gel chromatography (CtbCb/MeOH/NHs) to give the product as a off-white solid (45-76% yield). Preparation of 3-(l-Benzyl-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyriniidine. Stepl (l-BenzyI-piperidin-4-yl)-(2-chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-yl)-amine was prepared from 2,6-dichloro-5-nitro-4-morpholino-pyrimidine (1.5 g, 6.58 mmol) and 4-amino-1-benzylpiperidine (1.25 g, 6.58 mmol) following procedure 1 (step 1) to give the final product (2.0g, 70% yield); MS (ESI) m/z 433.1. Step 2 N4-(l-Benzyl-piperidin-4-yl)-2-chloro-6-morpholin-4-yl-pyrimidine-4,5-diaminewas prepared by reduction of (1-benzyl-piperidin-4-yl)-(2-chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-yl)-amine (1.0 g, 2.3 mmol) following procedure 1 (step 2) to give the final product (900 mg, 97% yield); MS (ESI) m/z 403.1. Step 3 3-(l-Benzyl-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-djpyrimidine was prepared from N4-(l -benzyl-piperidin-4-yl)-2-chloro-6-morpholin-4-yl-pyrimidine-4,5-diamine (500 mg, 1.24 mmol) and aqueous (0.5N) NaNC>2 solution (5 mL, 2.5 mmol) following procedure 1 (step 3) to give the final product (510 mg, 100% yield); MS (ESI) m/z 414.2. Preparation of 5-Chloro-3-ethyl-7-morphoIin-4-yl-3H-[l,2,3]triazolo[4,5- djpyrimidine. Stepl (2-Chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-yl)ethylamine was prepared from 2,6-dichloro-5-nitro-4-morpholino-pyrimidine (2.0 g, 7.17 mmol) and ethylamine (2 molar solution in THF, 3.94 mL, 7.89 mmol) following procedure 1 (step 1) to give the final product (2.1 g, 100 % yield); MS (ESI) m/z 288. Step 2 2-Chloro-N-4-ethyl-6-morpholin-4-yl-pyrimidine-4,5-diamine was prepared by the reduction of (2-chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-yl)ethylamine (600 mg, 2.08 mmol) following procedure 1 (step 2) to give the final product (374 mg, 70 % yield); MS (ESI) m/z 258. Step 3 5-ChIoro-3-ethyI-7-morpholin-4-yl-3H-[l,3]triazolo[4,5-d]pyrimidine was prepared from (2-chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-yl)-ethyl-amine (374 mg, 1.45 mmol) and aqueous (0.5N) NaN02 solution (3.75 mL, 1.88 mmol) following procedure 1 (step 3) to give the final product (250 mg, 64% yield); MS (ESI) m/z 269. Example 1 Preparation of 3-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yI-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol. 3-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol was prepared from 3-(l-benzyl-piperidin-4-yl)-5-chloro-7-morphoIin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine (100 mg, 0.24 mmol) and 3-hydroxyphenylboronic acid (60 mg, 0.36 mmol) following procedure 2 to give the titled product (70 mg, 61% yield). MS (ESI) m/z 472. Example 2 Preparation of 5-[3-(l-benzylpiperidin-4-yl)-7-morphoIin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyrimidin-2-amine. 1-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyrimidin-2-amine was prepared from 3-( 1 -benzyl-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidine (100 mg, 0.24 mmol) and 2-aminopyrimidine-4-boronic acid (66 mg, 0.48 mmol) following procedure 2 to give the titled product (52 mg, 46% yield); MS (ESI) m/z 473. Example 3 Preparation of 5-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin-3-ol. l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyrimidin-2-amine was prepared from 3-(l-benzyl-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine (160 mg, 0.38 mmol) and 3-methoxymethoxy-5-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-pyridine (151 mg, 0.57 mmol) following procedure 2 to give the intermediate 3-(l-benzyl-piperidin-4-yl)-5-(5-methoxymethoxy-pyridin-3-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine. The3-(1-benzyl-piperidin-4-yl)-5-(5-methoxymethoxy-pyridin-3-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine was dissolved in cone. HC1 (1 mL) and methanol (4 mL) and heated to reflux for 1 hr. The reaction mixture was cooled to 0 °C for 15 minutes and the titled product was collected by filtration (56 mg, 44% yield); MS (ESI) m/z 473. Preparation of 4-[3-(l-Benzyl-piperidin-4-yI)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]-phenylamine. 4-[3-(l-Benzyl-piperidin-4-yI)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]-phenylamine was prepared from 3-(l-benzyl-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H-[l,253]triazolo[4,5-d]pyrimidine(160mg, 0.38 mmol) and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenylamine (152 mg, 0.69 mmol) following procedure 2 to give the titled product (180 mg, 100% yield); MS (ESI) m/z 471.3. Examples 4 and 5 Preparation of l-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[123]t"azolo[4,5-d]pyrimidin-5-yllphenyl}-3-[2-(dimethyIamino)ethyI]ureaandN-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-2,2,2-trifluoroacetamide. To a stirred solution of triphosgene (72 mg, 0.24 mmol) in CHCI3 (2 mL) was added 4-[3-(l-benzyl-piperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]-phenylamine (TFA-salt, 100 mg, 0.14 mmol) at 0 °C. The reaction mixture was stirred for 30 min. N,N-dimethylethylenediamine (100 mg, 1.13 mmol) and NEt3 (36 mg, 0.36 mmol) in CHCI3 (1 mL) was added and the reaction mixture was stirred for additional lhr. The solvents were removed on a rotary evaporator and the crude mixture was purified by semi-prep-HPLC (TFA-method) to give l-{4-[3-(l-benzylpiperidin-4-yl)-7-rnorpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-[2-(dimethylamino)ethyl]urea (33 mg, 29% yield) MS (ESI) m/z 585.3 andN-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-2,2,2-trifluoroacetamide (33 mg, 39% yield) MS (ESI) m/z 567.2. Example 6 Preparation of l-{4-[3-(l-benzylpiperidin-4-yl)-7-morphoIin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yI]phenyl}-3-methylurea. To a stirred solution of triphosgene (113 mg, 0.38 mmol) in CHC13 (3 mL) was added 4-[3-(l-benzyl-piperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]-phenylamine (141 mg, 0.3 mmol) at 0 °C. The reaction mixture was stirred for 30 min. methylamine (2M in THF, 2 mL, 4 mmol) and the reaction mixture was stirred for additional lhr. The solvents were removed on a rotary evaporator and the crude mixture was purified by semi-prep-HPLC (TFA-method) to give l-{4- [3-(l-benzylpiperidin-4-yl)-7-moiphoiin-4-yi-3H-[l,2,3]friazoto 3-methylurea (69 mg, 35% yield) MS (ESI) m/z 528.3. Preparation of N-[2-(5-Chloro-7-morpholin-4-yl-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl)-ethyl] -acetamide. Stepl N-[2-(2-Chloro-6-morpholin-4-yI-5-nitro-pyrimidin-4-ylamino)-ethyl]-acetainide was prepared from 2,6-dichloro-5-nitro-4-moipholino-pyrimidine (500 mg, 1.8 mmol) and N-acetylethylendiamine (184 mg, 1.8 mmol) following procedure 1 (step 1) to give the final product (550 mg, 89% yield). MS (ESI) m/z 345.1. Step 2 N-[2-(5-Amino-2-chloro-6-morpholin-4-yl-pyrimidin-4-ylamino)-ethyI]-acetamide was prepared by reduction of N-[2-(2-chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-ylamino)-ethyl]-acetamide (550 mg, 1.59 mmol) following procedure 1 (step 2) to give the final product (500 mg, 100% yield). MS (ESI) m/z 315.1. Step 3 N-[2-(5-Chloro-7-morpholin-4-yl-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl)-ethyl]-acetamide was prepared from N-[2-(5-amino-2-chloro-6-morpholin-4-yl-pyrimidin-4-ylamino)-ethyl]-acetamide (500 mg, 1.24 mmol) and aqueous (0.5N) NaNC>2 solution (5 mL, 2.5 mmol) following procedure 1 (step 3) to give the final product (300 mg, 58% yield). MS (ESI) m/z 326. Example 7 Preparation of N-{2-[5-(3-hydroxyphenyl)-7-morpholin-4-yI-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]ethyl}acetamide. N-{2-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]ethyl}acetamide was prepared from N-[2-(5-chloro-7-morpholin-4-yl-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl)-ethyl]-acetamide (150 mg, 0.5 mmol) and 3-hydroxyphenyl-boronic acid (138 mg, 1.0 mmol) following procedure 2 to give the final product (56 mg, 29% yield); MS (ESI) m/z 384. Example 8 Preparation of N-(2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazoIo[4,5-d]pyrimidin-3-yl}ethyl)acetamide. N-(2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl}ethyl)acetamide was prepared fromN- [2-(5-chloro-7-morpholin-4-yl-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl)-ethyl]-acetamide(150mg, 0.5 mmol) and 3-(hydroxymethyi)-phenyi boronic acid (151 mg, 1.0 mmol) following procedure 2 to give the final product (52 mg, 26% yield); MS (ESI) m/z 398. Preparation of 5-Chloro-7-morpholin-4-yl-3-(3-pyrroUdin-l-yI-propyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine. Stepl (2-Chloro-6-morpholin-4-yI-5-nitro-pyrimidin-4-yI)-(3-pyrroIidin-l-yI-propyl)-amine was prepared from 2,6-dichloro-5-nitro-4-morpholino-pyrimidine (550 mg, 1.96 mmol) and 1-aminopropyl-pyrrolidine (301 mg, 2.35 mmol) following procedure 1 (step 1) to give the final product (500 mg, 69% yield); MS (ESI) m/z 371. Step 2 2-Chloro-6-morphoIin-4-yl-N-4-(3-pyrrolidin-l-yl-propyl)-pyrimidine-4,5-diamine was prepared by the reduction of (2-chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-yl)-(3-pyrrolidin-l-yl-propyl)-amine (500 mg, 1.34 mmol) following procedure 1 (step 2) to give the final product (350 mg, 76% yield); MS (ESI) m/z 341. Step 3 5-Chloro-7-morpholin-4-yl-3-(3-pyrrolidin-l-yI-propyI)-3H-[l,2,3]triazolo[4,5-djpyrimidine was prepared from 2-chloro-6-morpholin-4-yl-N-4-(3-pyrrolidin-l-yl-propyl)-pyrimidine-4,5-diamine (350 mg, 1.02 mmol) and aqueous (0.5N) NaNC>2 solution (3.5 mL, 1.75 mmol) following procedure 1 (step 3) to give the final product (150 mg, 42% yield); MS (ESI) m/z 352. Example 9 Preparation of 3-[7-morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yI]phenol. 3-[7-Morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol was prepared from 5-chloro-7-morpholin-4-yl-3-(3-pyrrolidin-l-yl-propyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine (50 mg, 0.14 mmol) and 3-hydroxyphenyl boronic acid (39 mg, 0.28 mmol) following procedure 2 to give the final product (34 mg, 58% yield); MS (ESI) m/z 410. Example 10 Preparation of {3-[7-morphoIin-4-yl-3-(3-pyrrolidin-l-yIpropyI)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}methanoI was prepared from 5-chloro-7- lmorphoIin-4-yl-3-(3-pyrTolidin-l-yl-propyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine (50 mg, 0.14 mmol) and 3-(hydroxymethyi)phenyi boronic acid (43 mg, 0.28 mmol) following procedure 2 to give the final product (34 mg, 57% yield); MS (ESI) m/z 424. Example 11 Preparation of 5-(lH-indazoI-4-yl)-7-morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine was prepared from 5-chloro-7-morpholin-4-yl-3-(3-pyrrolidin-l-yl-propyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidine (50 mg, 0.14 mmol) and 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-lH-indazole (68 mg, 0.28 mmol) following procedure 2 to give the final product (18 mg, 29% yield); MS (ESI) m/z 434. Preparation of 3-(l-Boc-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine. Stepl (l-Boc-piperidin-4-yl)-(2-chIoro-6-morphoIin-4-yl-5-nitro-pyrimidin-4-yl)-amine was prepared from 2,6-dichloro-5-nitro-4-morpholino-pyrimidine (2.0 g, 7.17 mmol) and 4-amino-1-BOC-piperidine (1.43 g, 7.17 mmol) following procedure 1 (step 1) to give the final product (3.1g, 99% yield); MS (ESI) m/z 443.2. Step 2 N4-(l-BOC-piperidin-4-yl)-2-chIoro-6-morpholin-4-yl-pyrimidine-4,5-diamine was prepared by reduction of (l-BOC-piperidm-4-yl)-(2-chloro-6-morpholin-4-yl-5-nitro-pyrimidin-4-yl)-amine (3.13 g, 7.08 mmol) following procedure 1 (step 2) to give the final product (2.8g, 96% yield); MS (ESI) m/z 413.2. Step 3 3-(l-Boc-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H-[l,2,3]triazoIo[4,5-d]pyrimidine was prepared from N4-(l-BOC-piperidin-4-yl)-2-chloro-6-morpholin-4-yl-pyrimidine-4,5-diamine (2.8g, 6.79 mmol) and aqueous (0.5N) NaNC>2 solution (24 mL, 12 mmol) following procedure 1 (step 3) to give the final product (2.1 g, 73 % yield). MS (ESI) m/z 424.2. Preparation of 4-[5-(5-Methoxymethoxy-pyridin-3-yl)-7-morphoIin-4-yI-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]-piperidine-l-carboxylic acid tert-butyl ester was prepared from 3-(l-BOC-piperidin-4-yl)-5-chloro-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-djpyrimidine (l.0g, 2.35 mmol) and 3-methoxymethoxy-5-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-pyridine (1.24 g, 4.7 mmol) following procedure 2 to give the titled product (1.3 g, 100%). Example 12 Preparation 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol. 3-(l-Boc-piperidin-4-yl)-5-(5-methoxymethoxy-pyridin-3-yi)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine was dissolved CHCI3 (15 mL) and TFA (5 mL) and stirred for 16 hours at 25 °C, than the solvents were removed under reduced pressure and the residue was dissolved in cone. HC1 (10 mL) and methanol (50 mL) and heated to reflux for 1 hr. The reaction mixture was cooled to 0 °C for 15 minutes and the titled compound was collected by filtration (56 mg, 44% yield); MS (ESI) m/z 383.3. Example 13 Preparation of 5-{3-[l-(2-furylmethyI)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}pyridin-3-ol. 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (17 mg, 0.044 mmol) was dissolved in methanol (1 mL) and 2-furalaldehyde (20 mg, 0.2 mmol), NaBH3CN (10 mg, 0.088 mmol, 1 eq) and ZnCb (10 mg, 0.044 mmol) was added. The suspension was stirred for 24 hours and the solvents were removed in vacuo. The crude product was dissolved in DMSO (2 mL), filtered and purified by semi-prep-HPLC using ACN/water/TFA as mobile phase. After unifying the product fraction and solvent removal, the product was obtained as a white solid. Yield: 16 mg, 35%; MS (ESI) m/z 463.4. Example 14 Preparation of 5-{3-[l-(4-fluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (17 mg, 0.044 mmol), 4-fluorobenzaldehyde (20 mg, 0.16 mmol), NaBH3CN (10 mg, 0.088 mmol), and ZnCl2 (10 mg, 0.044 mmol) as described in example 13 to give the product (15 mg, 31% yield); MS (ESI) m/z 491.2. Example 15 Preparation of 5-(3-{l-[(6-bromopyridin-3-yl)methyl]piperidin-4-yl}-7-morphoIin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (17 mg, 0.044 mmol), 6-bromonicotinaldehyde (20 mg, 0.11 mmol), NaBH3CN (10 mg, 0.088 mmol), and ZnCl2 (10 mg, 0.044 mmoi) as described in example 13 to give the product. Yield: 22 mg, 43%; MS (ESI) m/z 552. Example 16 Preparation of 5-(3-{l-[(5-bromopyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazoIo[4,5-d]pyrimidin-5-yl)pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (17 mg, 0.044 mmol), 5-bromopicolinaldehyde (20 mg, 0.11 mmol), NaBH3CN (10 mg, 0.088 mmol), and ZnCl2 (10 mg, 0.044 mmol) as described in example 13 to give the product (20 mg, 38% yield); MS (ESI) m/z 552. Example 17 Preparation of 5-[3-(l-{4-[3-(dimethylamino)propoxy]benzyI}piperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (17 mg, 0.044 mmol), 4-(3-dimethylamino-propoxy)-benzaldehyde (20 mg, 0.10 mmol), NaBH3CN (10 mg, 0.088 mmol), and ZnCl2 (10 mg, 0.044 mmol) as described in example 13 to give the product (14 mg, 27% yield); MS (ESI) m/z 573.3. Example 18 Preparation of 5-{3-[l-(3,4-difluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,23]triazolo[4,5-d]pyrimidin-5-yl}pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (17 mg, 0.044 mmol), 3,4-difluorobenzaldehyde (20 mg, 0.14 mmol), NaBH3CN (10 mg, 0.088 mmol), and ZnCl2 (10 mg, 0.044 mmol) as described in example 13 to give the product (15 mg, 31% yield); MS (ESI) m/z 508. Example 19 Preparation of 5-(3-{l-[(l-methyl-lH-pyrrol-2-yl)methyl]piperidin-4-yl}-7-morpholin-4-yI-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (20 mg, 0.052 mmol), l-methylpyrrole-2-carbaldehyde (20 mg, 0.18 mmol), NaBH3CN (20 mg, 0.18 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (18 mg, 46% yield); MS (ESI) m/z 475.2. Example 20 Preparation of 5-(3-{l-[(6-chloropyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-oI was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (20 mg, 0.052 mmol), 6-chloronicotinoylaldehyde (20 mg, 0.14 mmol), NaBH3CN (20 mg, 0.18 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (29 mg, 71 % yield); MS (ESI) m/z 508.2. Example 21 Preparation of 5-(3-{l-[(5-methyl-2-thienyl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol was prepared from 5-(7-morpholin-4-yI-3-piperidin-4-yI-3H-[I,2,3JtriazoIo[4,5-djpyrimidin-5-y0pyridm-3-oI (20 mg, 0.052 mmol), 5-methylthiophencarbaldehyde (20 mg, 0.14 mmol), NaBH3CN (20 mg, 0.18 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (22 mg, 56 % yield); MS (ESI) m/z 493.2. Example 22 Preparation of 5-[3-(l-methylpiperidin-4-yl)-7-morpholin-4-yI-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), aqueous (37%)-formaldehyde solution (20 mg, 0.24 mmol), NaBH3CN (20 mg, 0.18 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (14 mg, 35 % yield), MS (ESI) m/z 397.2. Example 23 Preparation of 5-{3-[l-(2,4-difluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), 2,4-difluorobenazaldehyde (20 mg, 0.14 mmol), NaBH3CN (20 mg, 0.18 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (15 mg, 32 % yield). MS (ESI) m/z 509.2. Example 24 Preparation of 5-(3-{l-[(l-methyl-lH-imidazol-5-yI)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-dJpyrimidin-5-yl)pyridin-3-oI. was prepared from 5- (7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmoi), I-methyl-imidazol-5-carbaldehyde (20 mg, 0.18 mmol), NaBH3CN (20 mg, 0.18 mmol), and ZnCk (20 mg, 0.18 mmol) as described in example 13 to give the product (14 mg, 31 % yield); MS (ESI) m/z 477.2. Example 25 Preparation of N-[3-({4-[5-(5-hydroxypyridin-3-yl)-7-morpholin-4-yl-3H-[l,3]triazoIo[4,5-d]pyrimidin-3-yl]piperidin-l-yl}methyl)pyridin-2-yI]-2,2-dimethylpropanamide was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), N-(3-formyl-pyridin-2-yl)-2,2-dimethyl-propionamide (20 mg, 0.1 mmol), NaBH3CN (20 mg, 0.18 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (5 mg, 10 % yield). MS (ESI) m/z 573.2. Example 26 Preparation of 5-(3-{l-[(4,5-dimethyl-2-thienyl)methyl]piperidin-4-yI}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-oI was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), 4,5-dimethylthiophencarbaldehyde (20 mg, 0.1 mmol), NaBH3CN (20 mg, 0.14 mmol), and ZnCb (20 mg, 0.18 mmol) as described in example 13 to give the product (10 mg, 20 % yield); MS (ESI) m/z 507.2. Example 27 Preparation of 5-[3-(l-butylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), butyraldehyde (20 mg, 0.1 mmol), NaBH3CN (20 mg, 0.36 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (11 mg, 26 % yield); MS (ESI) m/z 439.2. Example 28 Preparation of 5-(3-{l-[(4-benzylpiperazin-l-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[lr3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), 4-benzyl-piperazine-l-carbaldehyde (20 mg, 0.1 mmol), NaBH3CN (20 mg, 0.36 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (15 mg, 28 % yield); MS (ESI) m/z 571. Example 29 Preparation of 5-{7-morpholin-4-yl-3-[l-(lH-pyrroI-2-ylmethyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5-dlpyrimidin-5-yl}pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), pyrrole-2-carbaldehyde (20 mg, 0.21 mmol), NaBH3CN (20 mg, 0.36 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the titled product (9 mg, 20 % yield), MS (ESI) m/z 462. Example 30 Preparation of 5-(3-{l-[(l-methyl-lH-pyrazol-5-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), l-methylpyrrazole-6-carbaldehyde (20 mg, 0.18 mmol), NaBH3CN (20 mg, 0.36 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (16 mg, 33 % yield); MS (ESI) m/z 477.2. Example 31 Preparation of 5-{7-morpholin-4-yl-3-[l-(4-pyridin-4-ylbenzyl)piperidin-4-yl]-3H-[l,2,3]triazoIo[4,5-d]pyrimidin-5-yl}pyridin-3-ol was prepared from 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2J3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol (25 mg, 0.066 mmol), 1-4-pyridin-4-yl-benzaldehyde (20 mg, 0.18 mmol), NaBH3CN (20 mg, 0.36 mmol), and ZnCl2 (20 mg, 0.18 mmol) as described in example 13 to give the product (16 mg, 33 % yield). MS (ESI) m/z 550.2. Example 32 Preparation of 4-(3-Ethyl-7-morpholin-4-yl-3H-[l,23]triazoIo[4,5-d]pyrimidin-5-yl)-phenylamine was prepared from 5-chloro-3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-djpyrimidine (1.45 g, 5.40 mmol) 4-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-phenylamine (1.53 g, 7.03 mmol) following procedure 2 to give the titled product (1.63 g, 92% yield). MS (ESI) m/z 326. Example 33 Preparation of l-[4-(3-ethyl-7-morpholin-4-yl-3-[l,3]triazolo[4,5-d]pyrimidin-5-yI)phenyl]-3-pyridin-4-ylurea. To a stirred solution of triphosgene (68 mg, 0.23 mmol) in CH2C12 (5 mL) was added 4-(3thy]-7-morpholin-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yI> phenylamine (100 mg, 0.46 mmol) at 0 °C. The reaction mixture was stirred for 15 min and 4-aminopyridine (40 mg, 0.46 mmol) and NEt3 (64 uL, 0.46 mmol) was added and the reaction mixture was stirred for additional lhr. The solvents were removed on a rotary evaporator and the crude mixture was purified by semi-prep-HPLC (NH3-method) to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-4-ylurea (22 mg, 11 % yield) MS (ESI) m/z 446. Example 34 Preparation of l-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-7-morphoIin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyr]urea. To a stirred solution of triphosgene (90 mg, 0.31 mmol) in CHCI3 (1 mL) was added 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)-phenylamine (100 mg, 0.31 mmol) at 0 °C. The reaction mixture was stirred for 15 min and N,N-dimethylethylenediamine (82 mg, 0.93 mmol) andNEt3 (42 uL, 0.31 mmol) was added and the reaction mixture was stirred for additional lhr. The solvents were removed on a rotary evaporator and the crude mixture was purified by semi-prep-HPLC (NH3-method) to give l-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-7-morpholin-4-yl-3i/-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea (13 mg, 10 % yield) MS (ESI) m/z 440. Example 35 Preparation of l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2-methylpyridin-4-yl)urea. The title compound was prepared as described in the example above using triphosgene (74 mg, 0.25 mmol), 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)-phenylamine (100 mg, 0.31 mmol), 4-amino-2-methyI-pyridine (100 mg, 0.93 mmol) and NEt3 (430 uL, 0.44 mmol) in CH2C12 (3 mL) to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2-methylpyridin-4-yl)urea (13 mg, 9 % yield) MS (ESI) m/z 460. Example 36 Preparation of l-[4-(3-ethyl-7-morpholin-4-yl-3/?-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4/jT-l,2,4-triazol-4-yl)urea. The compound was prepared as described in the example above using triphosgene (69 mg, 0.23 mmol), 4-(3-ethyl-7-morpholin-4-yl-3H- f 1.2.3]triazolo[4.5-d]pyrimidin-5-yl)-phenylamine (150 mg, 0.46 mmol), 4-amino-l,2,4-triazole (116 mg, 1.38 mmol) and NEt3 (193 uL, 1.38 mmol) in CH2C12 (3 mL) to give l-[4-(3-ethyl-7-morpholin-4-yl-3i/-[l,23]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4H-l,2,4-triazoM-\1)urea (43 mg, 42% yield), MS (ESI) m/z 436.4. Example 37 Preparation of l-[4-(3-ethyl-7-morpho!in-4-yl-3H-[l,2,3]triazolo[4,5-d]pyriinidin-5-yl)phenyl]-3-(l,3-thiazol-2-yl)urea. The compound was prepared as described in the example above using triphosgene (46 mg, 0.15 mmol), 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)-phenylamine (100 mg, 0.31 mmol), 2-amino-thiazole (93 mg, 0.93 mmol) and NEt3 (129 pX, 0.93 mmol) in CH2C12 (2 mL) to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(l,3-thiazol-2-yl)urea(48 mg, 34 % yield). MS (ESI) m/z 452.3. Example 38 Preparation of 2-(4-aminophenyl)ethyl [4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamate. The compound was prepared as described in the example above using triphosgene (73 mg, 0.25 mmol), 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)-phenylamine (80 mg, 0.25 mmol), 4-amino-phenethyl alcohol (101 mg, 0.73 mmol) and NEt3 (102 uL, 0.73 mmol) in CH2C12 (2 mL) to give 2-(4-aminophenyl)ethyl [4-(3-ethyl-7-morpholin-4-yl-3#-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamate (15 mg, 12 % yield), MS (ESI) m/z 489.5. Example 39 [0002]Preparation of l-[4-(3-ethyI-7-morphoIin-4-yl-3/T-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylurea. To a stirred solution of 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)-phenylamine (150 mg, 0.46 mmol) in anhydrous CHCI3 (2 mL) was added pyridine-3-isocyanate (83 mg, 0.69 mmol) and NEt3 (97 uL, 0.69 mmol). The mixture was stirred for 18 hours and the solvents were removed in vacuo to obtain the crude product, which was purified by semi-prep-HPLC (NH3-method), to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-3-ylureaas off white solid (55 mg, 26% yield), MS (ESI) m/z 446.4. Example 40 Preparation of l-[4-(3-ethyl-7-morpholin-4-yl-31ir-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2-thienyl)urea. To a stirred solution of 4-(3-ethyl-7-morpholin-4-yl-3H-[I,2,3]triazolo[4,5-d]pyrimidin-5-yl)-phenylamine (150 mg, 0.46 mmol) in anhydrous CHCh (2 mL) was added thienyl-2-isocyanate (87 mg, 0.69 mmol) and NEt3 (97 u.L, 0.69 mmol). The mixture was stirred for 18 hours and the solvents were removed in vacuo to obtain the crude product, which was purified by semi-prep-HPLC (NH3-method), to give l-[4-(3-ethyl-7-morpholin-4-yl-3/f-[ 1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2-thienyl)urea as off white solid (90 mg, 43 % yield, MS (ESI) m/z 451.4. Example 41 Preparation of methyl 4-({[4-(3-ethyl-7-morpholin-4-yl-3i/-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}arnino)benzoate. To a stirred solution of 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)-phenylamine (3.26 g, 10.0 mmol) in anhydrous CH2CI2 (50 mL) was added a solution of methyl-4-isocyanatobenzoate (2.12 g, 12.0 mmol) in CH2CI2 (50 mL). The mixture was stirred for 8 hours and the solid was collected by filtration. The filter cake was washed with hexane (10 mL) and dried in a vacuum oven to give the product as off white solid (3.54g, 71% yield). MS (ESI) m/z 503.3. Example 42 Preparation of 4-({[4-(3-ethyl-7-morpholin-4-yl-3jff-[12,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoic acid. In a one-neck flask equipped with reflux condenser were suspended methyl 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzoate (3.54g, 7.1 mmol) in THF (20 mL), methanol (5 mL) and NaOH (5N, 5 mL, 25 mmol). The mixture was heated at reflux for 2 hours and cooled to 0° C and acidified (pHTiniidin-5-yI)phenyl)urea (40 mg, 0.087 mmol) at 25 °C. The reaction mixture was stirred for 30 min then NEt3 (121 uL, 0.87 mmol) and 1-methylpiperidin-4-amine (30 mg, 0.262 mmol) were added. Stirred for 2.5 hrs. and the solvent was removed in a N2 stream and the crude mixture was purified by HPLC (TFA-method) to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(l-methylpiperidin-4-yl)carbamoyl]amino}phenyl)urea as a TFA salt (4.5 mg, 7% yield), MS (ESI) m/z = 600.7 Example 268 1-(4-ethyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl]-3-[4-({[2-(4-methylpiperazin-l-yl)ethyl]carbamoyl}amino)phenyl]urea. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), l-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), 2-(4-methylpiperazin-l-yl)ethanamine (38 mg, 0.262 mmol), triethylamine (121 µL, 0.87 mmol), and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-({[2-(4-methylpiperazin-l-yl)ethyl]carbamoyl}amino)phenyl]urea as a TFA salt (35.5 mg; 48% yield), MS (ESI) m/z = 629.3 Example 269 N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]-4-methyl-l,4-diazepane-l-carboxamide. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), l-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), 1-methyl-1,4-diazepane (30 mg, 0.262 mmol), triethylamine (121 µL, 0.87 mmol) and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give N-(4-(3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)phenyl)-4-methyl-1,4-diazepane-l-carboxamide as a TFA salt (26.6 mg; 43% yield), MS (ESI) m/z = 600.3. Example 270 142-(dimethylamino)ethyl]-3-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]-l-methylurea. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), l-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), N1,N1,N2-trimethylethane-l,2-diamine (27 mg, 0.262 mmol), triethylamine (121 µL, 0.87 mmol) and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give l-[2-(dimethylamino)ethyl]-3-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]-l-methylureaas a TFA salt (29.8 mg; 49% yield), MS (ESI) m/z = 588.3. Example 271 l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(2-pyrrolidin-l-ylethyl)carbamoyl]amino}phenyl)urea . The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), l-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), 2-(pyrrolidin-l-yl)ethanamine (30 mg, 0.262 mmol), triethylamine (121 uL, 0.87 mmol), and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4- {[(2-pyrrolidin-1 -ylethyl)carbamoyl]amino}phenyl)urea as a TFA salt (27.9 mg; 45% yield), MS (ESI) m/z = 600.7 Example 272 N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]-4-pyrrolidin-l-ylpiperidine-l-carboxamide. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), 1-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), 4-(pyrrolidin-l-yl)piperidine (40 mg, 0.262 mmol), triethylamine (121 µL, 0.87 mmol), and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give N-(4-(3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)phenyl)-4- (pyrrolidin-l-yl)piperidine-l-carboxamide as a TFA salt (27.9 mg; 45% yield), MS (ESI) m/z = 640.3. Example 273 l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yI)phenyI]-3-(4-{[(pyridin-2-ylmethyl)carbamoyl]amino}phenyl)urea . The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), l-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), pyridin-2-ylmethanamine (30 mg, 0.262 mmol), triethylamine (121 uL, 0.87 mmol), and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(pyridin-2- ylmethyl)carbamoyl]amino}phenyl)urea as a TFA salt (22.8 mg; 37% yield), MS (ESI) m/z = 594.3 Example 274 N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-(l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]piperazine-l-carboxamide. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), l-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), piperazine (23 mg, 0.262 mmol), triethylamine (121 µL, 0.87 mmol), and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give N-(4-(3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)phenyl)piperazine-l-carboxamide as a TFA salt (3 mg; 5% yield), MS (ESI) m/z = 572.6 Example 275 4-ethyl-N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]piperazine-l-carboxamide. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), l-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), 1-ethylpiperazine (30 mg, 0.262 mmol), triethylamine (121 \xL, 0.87 mmol) and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give 4-ethyl-N-(4-(3-(4-(3-ethyl-7-morpholino- 3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)phenyl)piperazine-l-carboxamide as a TFA salt (27.6 mg; 44% yield), MS (ESI) m/z = 600.3. Example 276 l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(2-methoxyethyl)carbamoyl]amino}phenyl)urea. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), l-(4-aminophenyl)-3-(4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea (40 mg, 0.087 mmol), 2-methoxyethanamine (20 mg, 0.262 mmol), triethylamine (121 uL, 0.87 mmol) and methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(2-methoxyethyl)carbamoyl]amino}phenyl)urea as a TFA salt (5.4 mg; 11% yield), MS (ESI) m/z = 561.3. Example 277 Preparation of l-{4-[3-(l-methylethyl)-7-morpholin-4-yl-317-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-[4-(4-methylpiperazin-l-yl)phenyl]urea . To a stirred solution of triphosgene (109 mg, 0.37 mmol) in CH2Cl2 (4 mL) was added 4-(3-isopropyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (150 mg, 0.44 mmol) at 25 °C. The reaction mixture was stirred for 15 min and NEt3 ( 62 µL, 0.45 mmol) was added. Stirring was continued for 1 h and 4-(4-methylpiperazin-l-yl)aniline (258 mg, 0.43 mmol) and NEt3 (622 µL, 4.5 mmol) were added and the reaction mixture was stirred for additional 1 hr. The solvents were removed in a N2 stream and the crude mixture was purified by semi-prep-HPLC (TFA-method) to give 1 -[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-(4-methylpiperazin-l-yl)phenyl]urea (86 mg, 35% yield), MS (ESI) m/z 557.6. Example 278 Preparation of l-{4-[3-(l-methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-(4-nitrophenyl)urea. To a stirred solution of 4-(3-isopropyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (200 mg, 0.6 mmol) in anhydrous THF (4 mL) was added a solution of 4-nitrophenylisocyanat (118 mg, 0.72 mmol) in THF (1mL) The mixture was stirred for 8 hours and the yellow solid was collected by filtration. The filter cake was washed with hexane (1 mL) and dried in a vacuum oven to give the product l-{4-[3-(l- methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyI}-3-(4-nitrophenyl)urea as yellow solid (140 mg, 46% yield),MS (ESI) m/z 504.4.. Example 279 Preparation of N-({[4-(3-isopropyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]methanesulfonamide. To a stirred solution of l-(4-aminophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea (100mg, 0.21mmol) and NaOH aqueous (2.5N) (200 µL, 0.5 mmol) in THF (1mL) was added MeSO3Cl (20µL, 0.253 mmol) and the mixture was stirred for 2 hours. The formed precipitate was collected by filtration and washed with water and allowed to dry on the filter to give N-[4-({[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]methanesulfonamide as off white solid (92 mg, 79% yield)MS (ESI) m/z 552.2. Example 280 Preparation of l-(4-aminophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea. In a three-necked flask was suspended under nitrogen atmosphere l-{4-[3-(l-methylemyl)-7-morpholin-4-yl-3i/-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-(4-nitrophenyl)urea (200 mg, 0.4 mmol) and Pd/C (10%wet) (200 mg) in methanol (150 mL) and CH2Cl2 (50 mL). The mixture was hydrogenated at 1 atm pressure using a H2-ballon. After 1 hr the reaction was completed and the mixture was filtered over Celite and the filtrate was evaporated to dryness to give the product as brown solid l-(4-aminophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3i/-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea (180 mg, 95 % yield). MS (ESI) m/z 473. Example281 Preparation of l-(4-{[4-(dimethylamino)piperidin-l-yI]carbonyl}phenyl)-3-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl). To a stirred solution of triphosgene (21 mg, 0.70 mmol) in CHCl3 (1.5 mL) was added (S)-4-(3-ethyl-7-(3-methylmorpholino)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (30 mg, 0.088 mmol) at 25°C. The reaction mixture was stirred for 15 min and added triethylamine (18 µL, 0.132 mmol) stirred for 60 min. then added (4-aminophenyl)(4-(dimethylamino)piperidin-l-yl)methanone (65 mg, 0.264 mmol). Stirred for additional 30 min. and added triethylamine (104 µL, 0.748 mmol) then stirred overnight. The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give (S)-l-(4-(4-(dimethylamino)piperidine-l-carbonyI)phenyI)-3-(4-(3-ethyl-7-(3-rnethylmorpholino)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea as a TFA salt (31.2 mg, 49% yield). MS (ES) m/z = 613.3 Example 282 Preparation of l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)-3-{4-[(4-methylpiperazin-l-yl)carbonyl]phenyl}urea. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), (S)-4-(3-ethyl-7-(3-methylmorpholino)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (30 mg, 0.088 mmol), (4-aminophenyl)(4-methylpiperazin-l-yl)methanone (58 mg, 0.264 mmol) and triethylamine (123 µL, 0.88 mmol) in methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give 1-(4-{3-ethyl-7-[(35)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)-3-{4-[(4-methylpiperazin-l-yl)carbonyl]phenyl}urea as a TFA salt (18.4 mg; 30% yield), MS (ESI) m/z = 585.3. Example 283 Preparation of 4-{[(4-{3-ethyl-7-[(3S)-3-methyImorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}-N-(2-pyrrolidin-l-ylethyl)benzamide . The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), (S)-4-(3-ethyl-7-(3-methylmorpholino)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (30 mg, 0.088 mmol), 4-amino-N-(2-(pyrrolidin-l-yl)ethyl)benzamide (62 mg, 0.264 mmol) and triethylamine (123 µL, 0.88 mmol) in methylene chloride (1.5 mL). The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give 4-{[(4-{3-ethyl-7-[(35)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}-N-(2-pyrrolidin-l-ylethyl)benzamide as a TFA salt (24.8 mg, 40% yield), MS (ESI) m/z = 599.3 Example 284 Preparation of 4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}-N-2-piperidin-l-ylethyl)benzamide. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), (S)-4-(3-ethyl-7-(3-methylmorpholino)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (30 mg, 0.088 mmol), 4-amino-N-(2-(piperidin-l-yl)ethyl)benzamide 65 mg, 0.264 mmol) and triethylamine (123 µL, 0.88 mmol) in methylene chloride (1.5 mL) The solvent was removed m a N2-stream and the crude product was purified by HPLC (TFA-method) to give 4-{[(4-{3-ethyl-7-[(35)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}-N-(2-piperidin-l-ylethyl)benzamide as a TFA salt (8.7 mg, 14% yield), MS (ESI) m/z = 613.3. Example 285 Preparation of N-[2-(dimethylamino)ethy 1] -4- {[(4- {3-ethyl-7- [(35)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyI)carbamoyl]aniino}-N-methylbenzamide. The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), (S)-4-(3-ethyl-7-(3-methylmorpholino)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (30 mg, 0.088 mmol), 4-amino-N-(2-(dimethylamino)ethyl)-N-methylbenzamide (58 mg, 0.264 mmol) and triethylamine (123 pL, 0.88 mmol) in methylene chloride (1.5 mL) The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give N-[2-(dimethylamino)ethyl]-4-{[(4-{3-ethyl-7-[(35)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}-N-methylbenzamide as a TFA salt (8.5 mg, 14% yield), MS (ESI) m/z = 587.3. Example 286 Preparation of N-[2-(dimethylamino)ethyI]-4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)carbamoyl]amino}benzamide . The compound was prepared as described in the example above using triphosgene (21 mg, 0.70 mmol), (S)-4-(3-ethyl-7-(3-methylmorpholino)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (30 mg, 0.088 mmol), 4-amino-N-(2-(dimethylamino)ethyl)benzamide (55 mg, 0.264 mmol) and triethylamine (123 µL, 0.88 mmol) in methylene chloride (1.5 mL) The solvent was removed in a N2-stream and the crude product was purified by HPLC (TFA-method) to give N-[2-(dimethylamino)ethyl]-4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}benzamide as a TFA salt (27 mg, 45% yield), MS (ESI) m/z = 573.3. Example 287 Preparation of methyl 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazoIo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)pyridine-2-carboxylate WYE-132810-l To a stirred solution of triphosgene (274mg, 0.92 mmol) in THF (10 mL) was added 4-(3-ethyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline (500 mg, 1.54 mmol) at 25 °C. The reaction mixture was stirred for 15 min and NEt3 (213 µL, 1.54 mmol) was added. The mixture was stirred for 1 h and methyl 5-aminopicolinate (703 mg, 462 mmol) and NEt3 (2130 µL, 15.4 mmol) were added and the reaction mixture was stirred for additional 12 hr than CHCl3 (100 mL) were added and the organic layer were extracted with sat NH4Cl-sol (10 mL) and brine (10 mL) and the combined organic layers were dried over MgSO4. Filtration and solvent removal on a rotary evaporator gave the off-white product to give methyl 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)pyridine-2-carboxylate (530mg, 68 % yield), MS (ESI) m/z 504.2. Example 288 Preparation of 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)pyridine-2-carboxylic acid. To a stirred suspension of methyl 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)pyridine-2-carboxylate (530 mg, 1.04 mmol) in IPA( 5mL) was added NaOH aqueous (2N) (2 mL, 4 mmol) and the mixture was heated at reflux for 2 hours. The mixture was made acidic with 6N HC1. Upon acidification the product precipitated, which was collected by filtration to obtain as off white solid (100 mg, 19% yield),MS (ESI) m/z 490. Example 289 Preparation of l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo(4,5-d]pyrimidin-5-yl)phenyl]-3-{6-[(4-methylpiperazin-l-yl)carbonyl]pyridin-3-yl}urea . The compound was prepared as described in examples above using 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)pyridine-2-carboxylicacid(50 mg, 0.1 mmol), N-methylpiperazine (20 uL, 0.2 mmol) and NEt3 (50 µL, 0.4 mmol), HOBT (27 mg, 0.2 mmol) and EDCI (38 mg, 0.2 mmol) in anhydrous DMF (1mL). The solvents were removed in a N2-stream and the crude mixture was purified by semi-prep-HPLC (NH3-method) to give N-[2-(dimethylamino)ethyl]-5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)-N-methylpyridine-2-carboxamide (20 mg, 34 % yield)MS (ESI) m/z 572.2. Example 290 Preparation of A-[2-(dimethylamino)ethyI]-5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]tria2olo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)-iV-methylpyridine-2-carboxamide. The compound was prepared as described in examples above using 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[455-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)pyridine-2-carboxylic acid (50 mg, 0.1 mmol), N,N-dimethylethylenediamine (18 µL, 0.2 mmol) and NEt3 (50 pL, 0.4 mmol), HOBT (27 mg, 0.2 mmol) and EDCI (38 mg, 0.2 mmol) in anhydrous DMF (1mL). The solvents were removed in a N2-stream and the crude mixture was purified by semi-prep-HPLC (NH3-method) to give H-[2-(dimethylamino)ethyl]-5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]carbamoyl}amino)-Ar-methylpyridine-2-carboxamide (14mg, 18 % yield), MS (ESI) m/z 560. Biological Evaluation - mTOR kinase assay methods The routine human TOR assays with purified enzyme are performed in 96-well plates by DELFIA format as follows. Enzyme is first diluted in kinase assay buffer (10 mM HEPES (pH 7.4), 50 mM NaCl, 50 mM p-glycerophosphate, 10 mM MnCl2, 0.5 mM DTT, 0.25 mM microcystin LR, and 100 µg/mL BSA). To each well, 12 µL of the diluted enzyme is mixed briefly with 0.5 µL test inhibitor or the control vehicle dimethylsulfoxide (DMSO). The kinase reaction is initiated by adding 12.5 µL kinase assay buffer containing ATP and His6-S6K (substrate) to give a final reaction volume of 25 µL containing 800 ng/mL FLAG-TOR, 100 µM ATP and 1.25 µM His6-S6K. The reaction plate is incubated for 2 hours (linear at 1-6 hours) at room temperature with gentle shaking and then terminated by adding 25 µL Stop buffer (20 mM HEPES, pH 7.4), 20 mM EDTA, 20 mM EGTA). The DELFIA detection of the phosphorylated His6-S6K (Thr-389) is performed at room temperature using a monoclonal anti-P(T389)-p70S6K antibody (1A5, Cell Signaling) labeled with Europium-N1-ITC (Eu) (10.4 Eu per antibody, PerkinElmer). The DELFIA Assay buffer and Enhancement solution are purchased from PerkinElmer. The terminated kinase reaction mixture (45 µL) is transferred to a MaxiSorp plate (Nunc) containing 55 µL PBS. The His6-S6K is allowed to attach for 2 hours after which the wells are aspirated and washed once with PBS. DELFIA Assay buffer (100 uL) with 40 ng/mL Eu-P(T389)-S6K antibody is added. The antibody binding is continued for 1 hour with gentle agitation. The wells are then aspirated and washed 4 times with PBS containing 0.05% Tween-20 (PBST). DELFIA Enhancement solution (100 µL) is added to each well and the plates are read in a PerkinElmer Victor model plate reader. Fluorescence Polarization Assay for PI3K Materials Reaction Buffer: 20 mM HEPES, pH 7.5, 2 raM MgCl2, 0.05% CHAPS; and 0.01% BME (added fresh) Stop/Detection Buffer: 100 mM HEPES, pH 7.5, 4 mM EDTA, 0.05% CHAPS; ATP 20 mM in water; PIP2 (diC8, Echelon, Salt Lake City Utah, cat# P-4508) 1 mM in water (MW=856.5); GST-GRP 1.75 mg/mL or 1.4 mg/mL in 10% glycerol; Red detector (TAMRA) 2.5 µM; Plate: Nunc 384 well black polypropylene fluorescence plate. Methods PI3-Kinase reactions were performed in 5 µM HEPES, pH 7, 2.5 µM MgCl2, and 25 µM ATP, with diC8-PI(4,5)P2 (Echelon, Salt Lake City Utah) as substrate. Nunc 384 well black polypropylene fluorescent plates were used for PI3K assays. Reactions were quenched by the addition of EDTA to a final concentration of 10 µM. Final reaction volumes were 10 ml. For evaluation of PI 3-K inhibitors, 5 ng of enzyme and 2.5 µM of substrate was used per 10 ml reaction volume, and inhibitor concentrations ranged from 100 pM to 20 uM; the final level of DMSO in reactions never exceeded 2%. Reactions were allowed to proceed for one hour at 25°C. After I hour, GST-tagged GRP1 (general receptor for phosphoinositides) PH domain fusion protein was added to a final concentration of 100 nM, and BODIPY-TMRI(l,3,4,5)P4 (Echelon) was also added to a final concentration of 5 nM. Final sample volumes were 25 µl with a final DMSO concentration of 0.8%. Assay Plates were read on PerkinElmer Envision plate readers with appropriate filters for Tamra [BODIPY-TMRI(l,3,4,5)P4]. Data obtained were used to calculate enzymatic activity and enzyme inhibition by inhibitor compounds. In vitro cell culture growth assay methods: Cell Lines used are human pancreatic (PC3) and ovarian (OVCAR3) tumor cell lines. PC3 and OVCAR3 are plated in 96-well culture plates at approximately 3000 cells per well. One day following plating, various concentrations of PI3K inhibitors in DMSO are added to cells (final DMSO concentration in cell assays is 0.25%). Three days after drug treatment, viable cell densities are determined by cell mediated metabolic conversion of the dye MTS, a well- established indicator of cell proliferation in vitro. Cell growth assays are performed using kits purchased from Promega Corporation (Madison, WI), following the protocol provided by the vendor. Measuring absorbance at 490 nm generates MTS assay results. Compound effect on cell proliferation is assessed relative to untreated control cell growth. The drug concentration that conferred 50% inhibition of growth is determined as IC50 (uM). Table 1 shows the results of the described biological assays. TABLE 1 (Table Removed) While particular aspects of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention. It is intended that each of the patents, applications, and printed publications, including books, mentioned in this patent document be hereby incorporated by reference in their entirety. We Claims:- What is claimed is: 1. A compound of the Formula 1: (Formula Removed) or a pharmaceutical ly acceptable salt thereof, wherein A is -O-, -CH2O-, or-S(O)m-; m is 0, 1, or 2; Ar is phenyl, naphthyl, or a nitrogen-containing mono- or bicyclic heteroaryl; R1 is independently C1-C6alkyl, C6-C14aryl, C1-C9heteroaryl, C2-C6alkenyl, C2-C6alkynyl, or C3- C8cycloalkyl; or two R1 groups on the same carbon atom, when taken together with the carbon to which they are attached, optionally form a carbonyl (C=O) group; n is 0, 1, 2, or 3; R2 is independently halogen; C1-C6alkyl; C2-C6alkenyl; C1-C6alkoxy; C2-C6alkynyl; C3- C8cycloalkyl; C6-C14aryl; C1-C9heteroaryl; hydroxyl; C1-C6hydroxylalkyl-; -NR4R5; -NO2; - CHO; -CN; -C(O)NR4R5; R6C(O)NH-; -CO2H; -CF3; -OCF3; R4R5NC(O)NH-; or R6OC(O)NH-; r is 0, 1,2, 3,4, or 5; R4 and R5 are each independently H; (C1-C6alkoxy)carbonyl; C1-C6alkyl; C6-C14aryl, optionally substituted with R7R8NC(O)-, R7R8NC(O)NH-, CO2H, -CONH2, -CN, -NO2, R7R8N-, R7R8N-C1- C6alkylene, RVN-CrQalkylene-O-, R7R8N-CrC6alkylene-NH-, R7R8N-NH-, CrC9heteroaryl, C1-C9heteroaryl-O-, C1-C9heterocyclyl-O-, C1-C6alkyl, C1-C6alkoxy, C1-C6hydroxylalkyl-, C1- C9heterocycle, wherein the ring portion of the C1-C9heterocycle group is optionally substituted by C1-C6alkyl, halogen, NH2-C1-C6alkylene-, (C1-C6alkyl)-NH-C1-C6alkylene-, (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-, or (C1-C6alkoxy)carbonyl; C1-C9heteroaryl, optionally substituted by R7R8NC(O)-, R7R8NC(O)NH-, CO2H, -CONH2; -CN, -NO2, R7RSN, R7R8N-C1-C6alkylene, R7R8N-C1-C6alkylene-O-, R7R8N-C1-C6alkylene-NH-, R7R8N-NH-, C1-C9heteroaryl, C1-C9heteroaryl-O-, C1-C9heterocyclyl-O-, C1-C6alkyl, C1-C6alkoxy, C1-C6hydroxylalkyl-, C1-C9heterocycle, wherein the ring portion of the C1-C9heterocycle group is optionally substituted by C1-C6alkyl, halogen, NH2-C1-C6alkylene-, (C1-C6alkyO-NH-C1-C6alkylene-, (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-, or (C1-C6alkoxy)carbonyl-; C1-C9heterocycle optionally substituted by (C6-C14aryl)alkyl-OC(O)- or C1-C6alkyl; C3-C8cycloalkyl; heterocyclyl(C1-C6alkyl) optionally substituted with C1-C6alkyl; C1-C6alkyl-OC(O)N(C1-C3alkyl)C1-C6alkylene; NH2-C1-C6alkylene-; (C1-C6alkyl)-NH-C1-C6alkylene-; or (C1-CealkylXCrQalkyON-CrCealkylene-; or R4 and R5 when taken together with the nitrogen to which they are attached optionally form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle is optionally replaced with -N(H)-, -O-, or -S(O)p-; p is 0, 1 or 2; R6 is C1-C6alkyl; C6-C14aryl; (C6-C14aryl)alkyl, optionally substituted by NH2; or C1-C6perfluoroalkyl-; R7 and R8 are each independently H; C1-C6alkyl optionally substituted with C1-C6alkoxy; C1-C8acyl optionally substituted with NH2, (C1-C6alkyl)amino, or di(C1-C6alkyl)amino; (C1-C6alkyl)SO2- optionally substituted with NH2, (C1-C6alkyl)amino, or di(C1-C6alkyl)amino; (C1-C6alkyl)SO- optionally substituted with NH2, (C1-C6alkyl)amino, or di(C1-C6alkyl)amino; C6-C14aryl-; (C6-C14aryl)SO2-; (C6-C14aryl)SO-; aryl(C1-C6alkyl) optionally substituted with C1-C6alkoxy, C1-C6alkyl, or halo; C1-C9heteroaryl; (C1-C9heteroaryl)SO2-; (C1-C9heteroaryl)SO-; heterocyclylSO2-; heterocyclylSO-; C1-C6hydroxylalkyl; heteroaryl(C1-C6alkyl) optionally substituted with C1-C6alkoxy, C1-C6alkyl, or halo; heterocyclyl(C1-C6alkyl) optionally substituted with C1-C6alkyl; C1-C9heterocycle optionally substituted by (C6-C14aryl)alkyl-OC(O)-; NH2-C1-C6alkylene-; (C1-C6alkyl)-NH-C1-C6alkylene-; or (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alkylene-; or R7 and R8 when taken together with the nitrogen to which they are attached optionally form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle are optionally replaced with -N(R9)-, -O-, or -S(O)q-, and wherein the heterocycle is optionally substituted with from 1 to 3 substituents independently selected from C1-C6alkyl; (C1-C6alkyl)amino-, C6-C14aryl, di(C1-C6alkyl)amino-, H2N-, C1-C9heteroaryl, and C1-C9heterocycle; q is 0, 1 or 2; R9 is H or C1-C6alkyl; R3 is: (a) hydrogen; (b) C1-C6 alkyl optionally substituted with from 1 to 3 substituents independently selected from: (i) C1-C6alkoxy, (ii) NH2, (iii) (C1-C6alkyl)amino, (iv) di(C1-C6alkyl)amino, (v) CO2H, (vi) and (C1-C6alkoxy)carbonyl; (c) carboxyamidoalkyl optionally substituted with a substituent selected from: (i) halogen, (ii) and di(C1-C6alkyl)amino; (d) C1-C6perfluoroalkyl-; (e) C3-C8cycloalkyl; (f) C6-C14aryl optionally substituted with a substituent selected from: (i) -O-C1-C6alkylene-NH2, (ii) -COOH, (iii) C1-C6hydroxylalkyl, (iv) R10R11NC(O)-, (v) and (C1-C6alkoxy)carbonyl; (g) monocyclic C1-C6heterocycle optionally substituted with from 1 to 3 substituents independently selected from: (i) C1-C8acyl, wherein the C1-C8acyl is optionally substituted with a NH2, (ii) C1-C6alkyl, (iii) heteroaryl(C1-C6alkyl) wherein the ring portion of the heteroaryl(C1-C6alkyl) group is optionally substituted with from 1 to 3 substituents independently selected from: A) C1-C6alkylC(O)NH-, B) halogen, C) NH2, D) and C1-C6alkyl, (iv) heterocyclyl(C1-C6alkyl), wherein the ring portion of the heterocyclyl(C1-C6alkyl) group is optionally substituted by a (C6-C14aryl)alkyl, (v) (C6-C14aryl)alkyl, wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by 1 to 3 substituents independently selected from: A) halogen, B) C1-C6alkyl, C) di(C1-C6alkyl)amino-(C1-C6alkylene)-O-, D) and C1-C9,heteroaryl; (vi) and (C1-C6alkoxy)carbonyl; (h) heterocyclyl(C1-C6alkyl) optionally substituted with a substituent selected from: (i) C1-C6alkyl, (ii) C3-C8cycloalkyl, (iii) (C1-C6alkoxy)carbonyl, (iv) C1-C6alkylcarboxy, (v) (C6-C14aryl)alkyl wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by a: A) halogen, B) C1-C9heteroaryl, C) or di(C1-C6alkyl)amino-(C1-C6alkylene)-O-, (vi) heteroaryl(C1-C6alkyl) wherein the ring portion of the heteroaryl(C1-C6alkyl) group is optionally substituted by a halogen, (vii) and C1-C8acyl, wherein the C1-C8acyl is optionally substituted with from 1 to 3 independently selected halogens, (i) (C1-C6alkyl)-C(O)-NH-(C1-C6alkylene)-; G) heteroaryl(C1-C6alkyl); (k) (C6-C14aryl)alkyl wherein the ring portion of the (C6-C14aryl)alkyl group is optionally substituted by a: (i) C1C6H4C(O)NH-, (ii) (C1-C6alkoxy)carbonyl, (iii) CO2H, (iv) orR10RHNC(O); (1) C1-C6hydroxylalkyl; (m) or C1-Cgheteroaryl; R10 and R11 are each independently: (a) H; (b) C1-C6alkyl optionally substituted with a substituent selected from: (i) C1-C6alkylC(O)NH-, (ii) NH2, (iii) (C1-C6alkyl)amino, (iv) or di(C1-C6alkyl)amino, (c) C3-C8cycloalkyl; (d) C6-C14aryl optionally substituted with a substituent selected from: (i) halogen, (ii) and monocyclic C1-C6heterocycle wherein the monocyclic C1-C6heterocycle is optionally substituted with (C1-C6alkoxy)carbonyl; (e) C1-C9heteroaryl; (f) heteroaryl(C1-C6alkyl); (g) heterocyclyl(C1-C6alkyl); (h) (C6-C14aryl)alkyl, wherein the chain portion of the (C6-C14aryl)alkyl group is optionally substituted by a hydroxyl; (i) or monocyclic C1-Ceheterocycle optionally substituted with a (C1- C6alkoxy)carbonyl; or R10 and R11 when taken together with the nitrogen to which they are attached optionally form a 3- to 7- membered nitrogen-containing heterocycle wherein up to two of the carbon atoms of the heterocycle are optionally replaced with -N(H)-, -N(C1-C6alkyl)-, -N(C6-C14aryl)-, or -O-, and wherein the nitrogen-containing heterocycle is optionally substituted by a C1-C6alkyl; C6- C14aryl, (C1-C6alkoxy)C(O)NH-, or C1-C9heterocycle. 2. The compound of claim 1, wherein n is 0. 3. The compound of claim 1 or claim 2, wherein A is -O-. 4. The compound of any one of claims 1 to 3, wherein r is 1. 5. The compound of any one of claims 1 to 4 , wherein Ar represents phenyl. 6. The compound of claim 5, wherein Ar represents phenyl substituted in the 4-position by R2. 7. The compound of any one of claims 1 to 6, wherein R2 is -NHC(O)NR4R5. 8. The compound of claim 7, wherein R5 is H. 9. The compound of any one of claims 1 to 8, wherein R4 is C6-C14 aryl, optionally substituted with R7R8NC(O)-. 10. The compound of claim 9, wherein R4 is phenyl, substituted with R7R8NC(O)-. 11. The compound of claim 10, wherein R4 is phenyl, substituted in the 4-position with R7R8NC(O)-. 12. The compound of claim 11, wherein R7 is (C1-C6alkyl)(C1-C6aIkyl)N-C1-C6alkylene-. 13. The compound of any one of claims 1 to 12, wherein R8 is H. 14. The compound of claim 11, wherein R7 and R8 taken together with the nitrogen to which they are attached form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle are optionally replaced with -N(R9)-, -O-, or -S(O)q-. 15. The compound of claim 14, wherein R7 and R8 taken together with the nitrogen to which they are attached form a 6- membered nitrogen containing heterocycle wherein one of the carbon atoms of the heterocycle is replaced with -N(R9)-. 16. The compound of claim 15, wherein R9 is C1-C6alkyl. 17. The compound of any one of claims 1 to 16, wherein R is C1-C6alkyl. 18. The compound of claim 17, wherein R3 is ethyl. 19. The compound of claim 1, wherein n is 0, A is -O-, r is 1, Ar is phenyl, R is -NHC(O)NR4R5, R4 is C6-C14aryl, optionally substituted with R7R8NC(O)-, and R3 is C1-C6alkyl. 20. The compound of claim 1, wherein n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R5 is H, and R3 is ethyl. 21. The compound of claim 1, wherein n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 is (C1-C6alkyl)(C1-C6alkyl)N-C1-C6alklene-, R8 is H, R5 is H, and R3 is ethyl. 22. The compound of claim 1, wherein n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 and R8 taken together with the nitrogen to which they are attached form a 3- to 7- membered nitrogen containing heterocycle wherein up to two of the carbon atoms of the heterocycle are optionally replaced with -N(R9)-, -O-, or -S(O)q-, R5 is H, and R3 is ethyl. 23. The compound of claim 1, wherein n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 and R8 taken together with the nitrogen to which they are attached form a 6- membered nitrogen containing heterocycle wherein one of the carbon atoms of the heterocycle is replaced with -N(R9)-, R5 is H, and R3 is ethyl. 24. The compound of claim 1, wherein n is 0, A is -O-, r is 1, Ar is phenyl, substituted in the 4-position, R2 is -NHC(O)NR4R5, R4 is phenyl, substituted in the 4-position with R7R8NC(O)-, R7 and R8 taken together with the nitrogen to which they are attached form a 6- membered nitrogen containing heterocycle wherein one of the carbon atoms of the heterocycle is replaced with -N(R9)-, R9 is C1-C6alkyl, R5 is H, and R3 is ethyl. 25. A compound selected from the group consisting of: 3-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 5-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyrimidin-2-amine; 5-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin-3-ol; l-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-[2-(dimethylamino)ethyl]urea; N-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-2,2,2-trifluoroacetamide; l-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-methylurea; N-{2-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]ethyl}acetamide; N-(2-{5-[3-(hydroxymethyl]-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3- yl}ethyl)acetamide; 3-[7-morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; {3-[7-morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}methanol; 5-(1H-indazol-4-yl)-7-morpholin-4-yl-3-(3-pyrrolidin-l-ylpropyl)-3H-[l,2,3]triazolo[4,5- d]pyrimidine; 5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-{3-[l-(2-furylmethyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}pyridin-3-ol; 5-{3-[l-(4-fluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}pyridin-3-ol; 5-(3-{l-[(6-bromopyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)pyridin-3-ol; 5-(3-{l-[(5-bromopyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)pyridin-3-ol; 5-[3-(l-{4-[3-(dimethylamino)propoxy]benzyl}piperidin-4-yl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin-3-ol; 5-{3-[l-(3,4-difluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}pyridin-3-ol; 5-(3- {1 -[(1 -methyl-1 H-pyrrol-2-yl)methyl]piperidin-4-yl} -7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-(3-{l-[(6-chloropyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)pyridin-3-ol; 5-(3-{l-[(5-methyl-2-thienyl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)pyridin-3-ol; 5-[3-(l-methylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin- 3-ol; 5-{3-[l-(2,4-difluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,253]triazolo[4,5- d]p)Timidin-5-yl}pyridin-3-ol: 5-(3-{l-[(l-methyI-lH4mid2Zol-5-yI)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; N-[3-({4-[5-(5-hydroxypyridin-3-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]piperidin-l-yl}methyl)pyridin-2-yl]-2,2-dimethylpropanamide; 5-(3-{l-[(4,5-dimethyl-2-thienyl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-[3-( 1 -butylpiperidin-4-yl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5-yl]pyridin- 3-ol; 5-(3-{l-[(4-benzylpiperazin-l-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 5-{7-morpholin-4-yl-3-[l-(lH-pyrrol-2-ylmethyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-y I} pyridin-3-ol; 5-(3- {1 -[(1 -methyl-1 H-pyrazol-5-yl)methyl]piperidin-4-yl} -7-morpholin-4-yl-3H- [ 1.2,3]triazolo[4,5 -d]pyrimidin-5-yl)pyridin-3 -ol; 5-{7-morpholin-4-yl-3-[l-(4-pyridin-4-ylbenzyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}pyridin-3-ol; 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-4- ylurea; l-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 5-yl)phenyl]urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2- methylpyridin-4-yl)urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidln-5-yl)phenyl]-3-(4H-l,2,4- triazol-4-yl)urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(l,3-thiazol- 2-yl)urea; 2-(4-aminophenyl)ethyl [4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamate; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-3- ylurea; 1-[4-(3-ethyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2- thienyl)urea; methyl 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzoate; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzoic acid; N-[2-(dimethylamino)ethyl]-4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4- methylpiperazin-1-yl)carbonyl]phenyl }urea; N-[2-(dimethylamino)ethyl]-4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5 -yl)phenyl] carbamoyl} amino)-N-methylbenzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(2-hydroxyethyl)benzamide; N-[3-(dimethylamino)propyl]-4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]carbamoyl}amino)benzamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4- morpholin-4-ylpiperidin-1 -yl)carbonyl]phenyl} urea; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-[2-(4-methylpiperazin-l-yl)ethyl]benzamide; l-[4-(l,4'-bipiperidin-1'-ylcarbonyl)phenyl]-3-[4-(3-ethyl-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(pyridin-4-ylmethyl)benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl] carbamoyl} amino)-N-methy l-N-[2-(methylamino)ethy 1] benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(2-morpholin-4-ylethyl)benzamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(3R)-3- methylpiperazin-1 -yl]carbonyl}phenyl)urea; 4{[4K(3-ethyl-7-morpholin-4-yl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl] carbamoyl}amino)-N-[3 -(4-methy lpiperazin-1-yl)propyl]benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl} amino)-N-(2-piperidin-1 -ylethyl)benzamide; 1 - {4-[(3,3 -dimethylpiperazin-1 -yl)carbonyl]phenyl} -3-[4-(3 -ethyl-7-morpholin-4-yl-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; 1-[4-3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4- pyridin-2-ylpiperazin-l-yl)carbonyl]phenyl}urea; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-[(l-ethylpyrrolidin-2-yl)methyl]benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N,N-dimethylbenzamide; N-butyl-4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzamide; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)-N-(2-pyridin-2-ylethyl)benzamide; N-ethyl-4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzamide; benzyl 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)piperidine-l-carboxylate; l-[4-(3-ethyl-7-moqholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrirnidin-5-yl)phenyl]-3-piperidin-4- ylurea; 4-{3-ethyl-7-[(3S)-3-rnethylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}aniline; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-[4-(2-hydroxyethyl)phenyl]urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-(2-thienyl)urea; 1-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl} phenyl)-3 -[4-(hydroxymethy l)phenyl] urea; 1 -(4-{ 3-ethyl-7-[(3 S)-3-methylmorpholin-4-yl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3 -pyridin-4-ylurea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl} phenyl)-3 -pyridin-3 -ylurea; l-(4-{3-ethyl-7-[(3S)-3-methylmoipholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-(4-methoxyphenyl)urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-(4-fluorophenyl)urea; l-(4-cyanophenyl)-3-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenyl)urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-[4-(4-methylpiperazin-l-yl)phenyl]urea; 4-(3-cyclopropyl-7-moqholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline; l-[4-(3-cyclopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- pyridin-4-ylurea; l-[4-(3-cyclopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- pyridin-4-ylurea; l-[4-(3-cyclopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2- thienyl)urea; 4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)aniline; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin- 4-ylurea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin- 3-ylurea; l-[4-(hydroxymethyl)phenyl]-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4- morpholin-4-ylphenyl)urea; 1 -[4-(dimethylamino)phenyl]-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl] urea; 1-(4-fluorophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]urea; l-[2-(dimethylamino)ethyl]-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4- methoxyphenyl)urea; l-[4-(3-isopropyl-7-morpholin-4-yI-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4- methylphenyl)urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- methylurea; l-[(l-ethylpyrrolidin-2-yl)methyl]-3-[4-(3-isopropyl-7-morphoIin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]urea; 4-({[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)benzamide; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-isoxazol- 4-ylurea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(lH- pyrrol-3-yl)urea; l-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; tert-butyl 4- {2-[5-(3 -hydroxyphenyl)-7-morpholin-4-yl-3H- [ 1,2,3]triazolo[4,5 -d]pyrimidin-3- y 1] ethyl} piperazine-1 -carboxylate; 3-[7-morpholin-4-yl-3-(2-piperazin-l-ylethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-{3-[2-(4-benzoylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-{7-morpholin-4-yl-3-[2-(4-propionylpiperazin-l-yl)ethyl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 5-yl}phenol; 3-(3-{2-[4-(4-fluorobenzoyl)piperazin-l-yl]ethyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-(3-{2-[4-(3,4-difluorobenzoyl)piperazin-l-yl]ethyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-{3-[2-(4-isonicotinoylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenol; 3-(7-morpholin-4-yl-3-{2-[4-(phenylacetyl)piperazin-l-yl]ethyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5 -yl)phenol; 3-{3-[2-(4-acetylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-{3-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5- d]pyrimidin-5 -y 1}phenol; 3-{3-[2-(4-butyIpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-{3-[2-(4-isobutylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-(3-{2-[4-(3-fluorobenzyl)piperazin-l-yl]ethyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-{3-[2-(4-{4-[3-(dimethylamino)propoxy]benzyl}piperazin-l-yl)ethyl]-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenol; 3-(7-morpholin-4-yl-3-{2-[4-(pyridin-3-ylmethyl)piperazin-l-yl]ethyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; 3-(7-morpholin-4-yl-3-{2-[4-(lH-pyrrol-2-ylmethyl)piperazin-l-yl]ethyl}-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenol; 3-(3-{2-[4-(2-furylmethyl)piperazin-l-yl]ethyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5 -y l)phenol; 3-{3-[2-(4-benzylpiperazin-l-yl)ethyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; methyl 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-3- yl]benzoate; methyl 3-[5-(3-formylphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]benzoate; [(7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidine-3,5-diyl)di-3,l-phenylene]dimethanol; 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzoic acid; 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzamide; 3-{7-morpholin-4-yl-3 - {3-[(4-pyrrolidin-1 -ylpiperidin-1 -yl)carbonyl]phenyl} -3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenol; 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]-N- methylbenzamide; N-[2-(dimethylamino)ethyl]-3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]benzamide; 3-(7-morpholin-4-yl-5-{4-[(phenylcarbamoyl)amino]phenyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)benzoic acid; tert-butyl 3-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]azetidine-1 -carboxylate; 3-(3-azetidin-3-yl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenol; 3-{3-[l-(2-aminobenzoyl)azetidin-3-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-[3-(l-benzyIazetidin-3-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-(3-{l-[(6-fluoropyridin-3-yi)methyl]azetidin-3-yl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; (llbS)-11,11b-dimethyl-2,3,5,6,11,11b-hexahydro-lH-indolizino[8,7-b]indol-8-ol; diethyl 8-ethynyl-7-hydroxydibenzo[b,d]furan-3,4-dicarboxylate; tert-butyl 3-(7-morpholin-4-yl-5-{4-[(phenylcarbamoyl)amino]phenyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)azetidine-l-carboxylate; tert-butyl 3-(7-morpholin-4-yl-5-{4-[(2-thienylcarbamoyl)amino]phenyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)azetidine-l-carboxylate; 4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]aniline; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-pyridin-4-ylurea; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-pyridin-3-ylurea; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3-pyrimidin-5-ylurea; l-[4-(dimethylamino)phenyl]-3-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H- [1,2,3]triazoIo[4,5-d]pyrimidin-5-yl]phenyl}urea; l-[4-(2-hydroxyethyl)phenyl]-3-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H- [ 1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}urea; tert-butylmethyl{2-[({4-[7-morpholin-4-yl-3-(2,2)2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl]phenyl}carbamoyl)amino]ethyl}carbamate; l-[2-(methylamino)ethyl]-3-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}urea; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-(2-thienyl)urea; l-{4-[7-morpholin-4-yl-3-(2,2,2-trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3-(3 -thienyl)urea; tert-butyl4-[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]piperidine-1 -carboxylate; 3-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenol; 3-{7-morpholin-4-yl-3-[l-(lH-pyrrol-2-ylmethyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5 -yl }phenol; 3-[3-(l-{4-[3-(dimethylamino)propoxy]benzyl}piperidin-4-yl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-{3-[l-(4-fluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; tert-butyl 4-[5-(2-aminopyrimidin-5-yl)-7-moqholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]piperidine-1-carboxylate; 3-{7-morpholin-4-yl-3-[l-(pyridin-2-ylmethyl)piperidin-4-yl]-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenol; tert-butyl 4-(7-morpholin-4-yl-5-{4-[(pyridin-3-ylcarbamoyl)amino]phenyl}-3H- [ 1,2,3]triazolo[4,5-d]pyrimidin-3-yl)piperidine-1 -carboxylate; tert-butyl4-{5-[4-({[2-(dimethylamino)ethyl]carbamoyl}amino)phenyl]-7-morpholin-4-yl-3H- [ 1,2,3]triazolo[4,5-d]pyrimidin-3-yl }piperidine-1 -carboxylate; l-[2-(dimethylarnino)ethyl]-3-[4-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]urea; l-[2-(dimethylamino)ethyl]-3-(4-{3-[l-(4-fluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H- [1,2,3]triazolo[4,5-d]pyrimidin-5-yl }phenyl)urea; I-[2-(dimethylamino)ethyl]-3-(4-{7-morpholin-4-yl-3-[l-(pyridin-3-ylmethyl)piperidin-4-yl]- 3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; l-[4-(3-{l-[(6-bromopyridin-3-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[2-(dimethylamino)ethyl]urea; l-(4-{3-[l-(4-chloro-2-fluorobenzyl)piperidin-4-yl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl}phenyl)-3-[2-(dimethylamino)ethyl]urea; l-[2-(dimethylamino)ethyl]-3-[4-(3-{l-[(6-fluoropyridin-3-yl)methyl]piperidin-4-yl}-7- morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; l-[2-(dimethylamino)ethyl]-3-[4-(3-{l-[(5-methyl-2-thienyl)methyl]piperidin-4-yl}-7- morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]urea; 1 -{4-[3-( 1 -butylpiperidin-4-yl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-[2-(dimethylamino)ethyl]urea; l-[2-(dimethylamino)ethyl]-3-(4-{7-morpholin-4-yl-3-[l-(4-pyridin-4-ylbenzyl)piperidin-4-yl]- 3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; l-[2-(dimethylamino)ethyl]-3-(4-{7-morpholin-4-yl-3-[l-(lH-pyrrol-2-ylmethyl)piperidin-4-yl]- 3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; l-[2-(dimethylamino)ethyl]-3-{4-[3-(l-{4-[3-(dimethylamino)propoxy]benzyl}piperidin-4-yl)-7- morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}urea; l-[4-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- pyridin-3-ylurea; l-{4-[3-(l-methylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3 -pyridin-3-ylurea; tert-butyl 4-[5-(4-{[(4-fluorophenyl)carbamoyl]amino}phenyl)-7-moqholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl]piperidine-l-carboxylate; tert-butyl 4-(7-morpholin-4-yl-5- {4-[(pyridin-4-ylcarbamoyl)amino]phenyl} -3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl)piperidine-l-carboxylate; l-[4-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3- pyridin-4-ylurea; tert-butyl 4-(5-{4-[(methylcarbamoyl)amino]phenyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)piperidine-1-carboxylate; tert-butyl4-[5-(4-{[(methoxycarbonyl)carbamoyl]amino}phenyl)-7-morpholin-4-yl-3H- [ 1,2,3]triazolo[4,5-d]pyrimidin-3-yl]piperidine-1 -carboxylate; l-{4-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3 -(3-chloropheny l)urea; 5-(3-{ 1-[(2-amino-l ,3-thiazol-5-yl)methyl]piperidin-4-yl}-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3-ol; 3-{3-[(l-ethylpyrrolidin-2-yl)methyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; {5-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]pyridin-3 -yl} methanol; [5-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)pyridin-3- yl] methanol; 4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)-2-methoxyaniline; [3-(7-morpholin-4-yl-3-piperidin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]methanol; {3-[3-(l-benzylpiperidin-4-yl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}methanol; 4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]aniline; l-{4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-(4-methylphenyl)urea; l-{4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l52,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3 -(4-fluorophenyl)urea; l-{4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl} -3-pyridin-3-ylurea; 4-[({4-[3-(2,2-dimethoxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}carbamoyl)amino]benzamide; l-{4-[3-(2-hydroxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- . pyridin-4-ylurea; l-{4-[3-(2-hydroxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- pyridin-3-ylurea; l-{4-[3-(2-hydroxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- (4-methoxyphenyl)urea; l-{4-[3-(2-hydroxyethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- phenylurea; tert-butyl 3-{[5-(4-aminophenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}azetidine-l-carboxylate; tert-butyl 3-[(7-morpholin-4-yl-5-{4-[(phenylcarbamoyl)amino]phenyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl)methyl]azetidine-1 -carboxylate; l-{4-[3-(azetidin-3-ylmethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-phenylurea; l-(4-{3-[(l-benzoylazetidin-3-yl)methyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 5-yl }phenyl)-3 -phenylurea; l-(4-{3-[(l-benzylazetidin-3-yl)methyl]-7-morpholin-4-yI-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenyl)-3-phenylurea; l-[4-(3-{[l-(4-fluorobenzyl)azetidin-3-yl]methyl}-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]-3-phenylurea; 1 -[4-(7-morpholin-4-yl-3-{[1-(4-pyridin-4-ylbenzyl)azetidin-3-yl]methyl }-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-phenylurea; l-(4-{3-[(l-{4-[3-(dimethylamino)propoxy]benzyl}azetidin-3-yl)methyl]-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)-3-phenylurea; 3-[7-moqholin-4-yl-3-(2-piperidin-l-ylethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-[7-morpholin-4-yl-3-(2-pyridin-2-ylethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 4-chloro-N-(4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}phenyl)benzamide; l-{4-[7-morpholin-4-yl-3-(tetrahydro-2H-pyran-4-yl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}-3-pyridin-4-ylurea; l-[4-(3-methyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-pyridin-3- ylurea; l-[4-(3-methyl-7-rnorpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(2- thienyl)urea; l-[4-(3-methyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(3- thienyl)urea; 3-{3-[4-(dimethylamino)butyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-{3-[4-(methylamino)butyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenol; 3-[3-(4-aminobutyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-[7-morpholin-4-yl-3-(4-pyrrolidin-l-ylbutyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenol; 3-{3-[4-(4-benzylpiperazin-l-yl)butyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl} phenol; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- methylbenzamide; tert-butyl4-[(4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yljmethyl }benzoyl)amino]piperidine-1 -carboxylate; tert-butyl [l-(4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}benzoyl)piperidin-4-yl]carbamate; N-(2-acetamidoethyl)-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl}benzamide; 4- {[5 -(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5 -d]pyrimidin-3-yl]methyl} -N- (3-pyrrolidin-1-ylpropyl)benzamide; N-benzyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yljmethyl }benzamide; 4-{[5-(3-hydroxyphenyl)-7-raorpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- (2-pyrrolidin-1 -ylethyl)benzamide; N-[2-(dimethylamino)ethyl]-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl}benzamide; N-[3-(dimethylamino)propyl]-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- pyridin-3-ylbenzamide; N-(4-fluorophenyl)-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl}benzamide; tert-butyl4-{4-[(4-{[5-(3-hydroxyphenyl)-7-moq)holin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- i-yl]methyl}benzoyl)amino]phenyl}piperazine-l-carboxylate; N-ethyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methy 1} benzamide; N,N-diethyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl} benzamide; N-cyclopropyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl} benzamide; N-tert-butyl-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}benzamide; 4- {[5 -(3 -hydroxyphenyl)-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-3 -yl]methyl} -N- (2-phenylethyl)benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- [(1S)-1 -phenylethyl]benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- [2-( 1 H-indol-3 -yl)ethyl]benzamide; N-(2-hydroxy-2-phenylethyl)-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl} benzamide; 3-{7-morpholin-4-yl-3-[4-(piperidin-l-ylcarbonyl)benzyl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl}phenol; 3-{7-morpholin-4-yl-3-[4-(pyrrolidin-l-ylcarbonyl)benzyl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 5-yl}phenol; 3-(7-morpholin-4-yl-3-{4-[(4-phenylpiperazin-l-yl)carbonyl]benzyl}-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenol; N-(2-furylmethyl)-4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl]methyl}benzamide; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]methyl}-N- [2-(lH-imidazol-5-yl)ethyl]benzamide; tert-butyl {5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 3-yl}acetate; tert-butyl [5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yljacetate; tert-butyl (7-morpholin-4-yl-5-{4-[(pyridin-4-ylcarbamoyl)amino]phenyl}-3H- [ 1,2,3 ]triazolo [4,5 -d]pyrimidin-3 -y l)acetate; 2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl}-N- pyridin-3-ylacetamide; 2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl}-N- methylacetamide; 2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl}acetamide; N-(4-fluorophenyl)-2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-3-yl}acetamide; N-[2-(dimethylamino)ethyl]-2-{5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H- [l,2,3]triazolo[4,5-d]pyrimidin-3-yl}acetamide; {5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl}acetic acid; methyl 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- y l]methy 1} benzoate; 4-{[5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3- yl]methyl}benzoic acid; methyl 4-({5-[3-(hydroxymethyl)phenyl]-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 3-yl} methyl)benzoate; methyl 4-{[5-(3-fluoro-5-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin- 3-yl]methyl}benzoate; and [5-(3-hydroxyphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]aceticacid. 26. A compound selected from the group consisting of: 1 - {4-[(2,2-dimethylhydrazino)carbonyl]phenyl} -3 -[4-(3 -ethyl -7-morpholin-4-yl-3H- [ 1,2,3 ]triazolo [4,5 -d]pyrimidin-5 -y l)pheny ljurea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4- nitrophenyl)urea; l-(4-aminophenyl)-3-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]urea; N-[4-({[4-(3-ethyl-7-morpholm-4-yl-3H-[l,253]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]-N2,N2-dimethylglycinamide; 3-[5-(4-{[(4-{[2-(dimethylamino)ethyl]carbamoyl}phenyl)carbamoyl]amino}phenyl)-7- morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-3-yl]benzoicacid; 4-[({4-[3-(3-carbamoylphenyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl]phenyl}carbamoyl)amino]-N-[2-(dimethylamino)ethyl]benzamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(pyridin- 4-ylmethy l)amino] phenyl} urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(pyridin- 3 -y lmethy l)amino]phenyl} urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(6- fluoropyridin-3-yl)methyl]amino}phenyl)urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(6- methoxypyridin-3-yl)methyl]amino}phenyl)urea; N-[2-(dimethylamino)ethyl]-4-[({4-[3-(l-methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl]phenyl}carbamoyl)amino]benzamide; l-{4-[3Kl-methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3- {4-[(4-methylpiperazin-l-yl)carbonyl]phenyl}urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{4-[(4- methy lpiperazin-1 -yl)methy l]phenyl} urea; l-[4<3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-(4- methylpiperazin-1 -yl)phenyl]urea; 4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl} amino)-N-pyridin-3 -ylbenzamide; N-[4-({ [4-(3-ethyl-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]-4-methylpiperazine-l-carboxamide; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]pyridine-4-carboxamide; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[455-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]morpholine-4-carboxamide; 3-(dimethylamino)-N-[4<{[43-ethyl-7-morpholin-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]benzamide; l-[2-(dimethylamino)ethyl]-3-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5 -y l)phenyl] carbamoyl} amino)phenyl] urea; 4-(dimethylamino)-N-[4<{[4<3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]piperidine-l-carboxamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(l- methylpiperidin-4-yl)carbamoyl] amino } phenyl)urea; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-({[2-(4- methylpiperazin-l-yl)ethyl]carbamoyl}amino)phenyl]urea; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- y l)phenyl ] carbamoyl} amino)phenyl] -4-methy 1-1,4-diazepane-1 -carboxamide; l-[2-(dimethylamino)ethyl]-3-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]carbamoyl}amino)phenyl]-l-methylurea; l.[4.(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(2- pyrrolidin-l-ylethyl)carbamoyl]amino}phenyl)urea; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl} amino)phenyl]-4-pyrrolidin-1 -ylpiperidine-1 -carboxamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-(4-{[(pyridin- 2-ylmethyl)carbamoyl]amino}phenyl)urea; N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]piperazine-l-carboxamide; 4-ethyl-N-[4-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl} amino)phenyl]piperazine-1 -carboxamide; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[455-d]pyrimidin-5-yl)phenyl]-3-(4-{[(2- methoxyethyl)carbamoyl]amino}phenyl)urea; l-{4-[3-(l-methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-[4- (4-methylpiperazin-1 -yl)phenyl]urea; l-{443Kl-methylethyl)-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl}-3-(4- nitrophenyl)urea; N-[4-({ [4-(3-isopropyl-7-morpholin-4-yl-3H-[ 1,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)phenyl]methanesulfonamide; l-(4-aminophenyl)-3-[4-(3-isopropyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]urea; l-(4-{[4-(dimethylamino)piperidin-l-yl]carbonyl}phenyl)-3-(4-{3-ethyl-7-[(3S)-3- methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)urea; l-(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl }phenyl)-3 - {4- [(4-methylpiperazin-1 -yl)carbonyl]pheny 1} urea; 4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl }phenyl)carbamoyl]amino } -N-(2-pyrrolidin-1 -ylethyl)benzamide; 4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl }phenyl)carbamoyl]amino} -N-(2-piperidin-1 -ylethyl)benzamide; N-[2-(dimethy lamino)ethyl]-4- {[(4- {3 -ethyl-7-[(3 S)-3 -methylmorpholin-4-yl] -3 H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}-N-methylbenzamide; N-[2-(dimethylamino)ethyl}-4-{[(4-{3-ethyl-7-[(3S)-3-methylmorpholin-4-yl]-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl}phenyl)carbamoyl]amino}benzamide; methyl 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl}amino)pyridine-2-carboxylate; 5-({[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5- yl)phenyl]carbamoyl} amino)pyridine-2-carboxyHe acid; l-[4-(3-ethyl-7-morpholin-4-yl-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-{6-[(4- methylpiperazin-l-yl)carbonyl]pyridin-3-yl}urea; and N-[2-(dimethylamino)ethyl]-5-({ [4-(3-ethyl-7-morpholin-4-yl-3H-[l ,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl]carbamoyl}amino)-N-methylpyridine-2-carboxamide. 27. A compound selected from the group consisting of: N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(3-methyl-7-morpholino-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-4-(3-(4-(3-methyl-7-morpholino-3H-[l,2,3]triazolo[4,5- d]pyrimidin-5-yl)phenyl)ureido)benzamide; 1-(4-(3-methyl-7-morpholino-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-3-(4-(4- methylpiperazine-1 -carbonyl)phenyl)urea; l-(4-(4-(dimethylamino)piperidine-l-carbonyl)phenyl)-3-(4-(3-methyl-7-morpholino-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea; N-(2-(dimethylamino)ethyl)-N-methyl-4-(3-(4-(7-morpholino-3-(2,2,2-trifluoroethyl)-3H- [l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)ureido)benzamide; N-(2-(dimethylamino)ethyl)-4-(3-(4-(7-morpholino-3-(2,2,2-trifluoroethyl)-3H- [1,2,3 ]triazolo [4,5 -d]pyrimidin-5 -yl)phenyl)ureido)benzamide; 1 -(4-(4-methylpiperazine-1 -carbonyl)phenyl)-3-(4-(7-morpholino-3-(2,2,2-trifluoroethyl)-3H- [ 1,2,3 Jtriazolo [4,5 -d]pyrimidin-5 -yl)phenyl)urea; and 1 -(4-(4-(dimethylamino)piperidine-1 -carbonyl)phenyl)-3-(4-(7-morpholino-3 -(2,2,2- trifluoroethyl)-3H-[l,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)urea. 28. A composition comprising the compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 27 and a pharmaceutically acceptable carrier. 29. The composition of claim 28 wherein the pharmaceutically acceptable carrier is suitable for oral administration and the composition comprises an oral dosage form. 30. A method of inhibiting PI3K, comprising administering to a mammal the compound or a pharmaceutically acceptable salt of the compound of any one of claim 1 to 29, in an amount effective to inhibit PI3K. 31. A method of inhibiting mTOR, comprising administering to a mammal the compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 27, in an amount effective to inhibit mTOR. 32. A method of treating advanced renal cell carcinoma, comprising administering to a mammal in need thereof the compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 27, in an amount effective to treat advanced renal cell carcinoma. 33. A method of treating acute lymphoblastic leukemia, comprising administering to a mammal in need thereof the compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 27, in an amount effective to treat acute lymphoblastic leukemia. 34. A method of treating malignant melanoma, comprising administering to a mammal in need thereof the compound or a pharmaceutically acceptable salt of the compound of any one of claims 1 to 27, in an amount effective to treat malignant melanoma. 35. A method of treating soft-tissue or bone sarcoma, comprising administering to a mammal in need thereof the compound or a pharmaceuticalry acceptable salt of the compound of any one of claim 1 to 27s, in an amount effective to treat soft-tissue or bone sarcoma. 36. A method of synthesizing a compound of claim 1 comprising reacting a boronic acid of the formula (R2)r-Ar-B(OH)2 with the 5-chloro-3H-[l,2,3]triazolo[4,5-d]pyrimidine 2: (Formula Removed) wherein X is halo and A, Ar, R1, n, R2, r, and R3, are as defined in claim 1; (Formula Removed) thereby producing the 3H-[l,2,3]triazolo[4,5-d]pyrimidine 1. 37. The method of claim 36 further comprising further comprising: (a) reacting the 2,4,6- trihalo-5-nitropyrimidine of Formula 3 with an amine 4 to substitute the halogen (Formula Removed) atom at position 4 of the pyrimidine: (Formula Removed) thereby producing 5: (Formula Removed) (b) reacting dihalo pyrimidine 5 with amine R3-NH2 replacing the halogen atom at position 6 of the pyrimidine ring with radical R3-NH-; c) reducing the product of the proceeding reaction to convert the nitro group at position 5 of the pyrimidine ring to an amino group without removing the halogen atom at position 2 of the pyrimidine; d) diazotizing and cyclizing the diaminopyrimidine; (Formula Removed) thereby producing 3H-[l,2,3]triazolo[4,5-d]pyrimidine 2.